










Clinical profile and management of women treated for endometrial  














A dissertation submitted to the Nelson R Mandela School of 
Medicine, Faculty of Health Sciences, and University of KwaZulu 
Natal South Africa in partial fulfilment of the requirements for MMed 








This study represents original work by the author and has not been submitted in any 
form to another university. Where use was made of the work of others, it has been 
duly acknowledged in the text. 
 
The research topic is titled “Clinical profile and management of women treated  








Candidate’s signature……………………………….      Date.…/……/…... 
Dr. L. Augustine 
 
 
Supervisor’s signature…………………………    Date..../……/…... 












I am truly indebted to the individuals who have made invaluable contributions to this 
study.  I am grateful to Professor J.S. Bagratee for his critical comments, advice and 
support. I appreciate all of the support rendered to me by the management and 
administrative support staff at Inkosi Albert Luthuli Central Hospital. I am grateful to 
the statisticians for all of their support in producing this submission.  
 






























IALCH  Inkosi Albert Luthuli Central Hospital  
ICD   International Classification of Disease 
HIV   Human Immunodeficiency Syndrome 
HRT   Hormone Replacement Therapy 
LGSIL   Low Grade Squamous Intraepithelial Lesion 
HGSIL   High Grade Squamous Intraepithelial Lesion 
HPV   Human Papilloma Virus 
COC   Combined Oral Contraceptive 
BMI   Body Mass Index 
TAH    Total Abdominal Hysterectomy                                                                                 
TAH + BSO Total Abdominal Hysterectomy and Bilateral Salpingo-
Oophorectomy 
VH    Vaginal Hysterectomy                                             
LAVH     Laparoscopically Assisted Vaginal Hysterectomy  
FIGO   International Federation of Gynaecology and Obstetrics 
MMMT  Malignant Mixed Müllerian Tumour 
MRI    Magnetic Resonance Imaging 
SD   Standard Deviation 
ASIR   Age standardised incidence ratios 
PCOS   Polycystic ovarian syndrome 
DD&C   Diagnostic dilatation and curettage 
Pap    Papanicolaou 
PR   Progesterone receptor 
ER   Oestrogen receptor 











List of tables         Page No. 
 
Table 1 Lifetime risk of endometrial carcinoma among the different racial groups in 
South Africa (2010)        2 
 
Table 2 Age standardised incidence ratios (ASIR) of endometrial carcinoma  
  in South African, American and United Kingdom subpopulations  2 
 
Table 3 Differences between type I and type II endometrial carcinomas  8 
 
Table 4 Risk of lymph node involvement in patients with clinical stage I disease 24 
 
Table 5 Endometrial carcinoma - FIGO surgical staging and overall survival rate 32 
 
Table 6 Yearly distribution of endometrial carcinoma at IALCH   37 
 
Table 7 Comparison of demographic details in black and Indian populations 38 
 
Table 8 Demographic details of women with endometrial carcinoma  39 
 
Table 9 Histopathological results       40 
 
Table 10 Comparison of histopathological results in black and Indian populations 40 
 
Table 11 Number of endometrial carcinomas by age     41 
 
Table 12 Predisposing factors affecting endometrial carcinoma   42 
 
Table 13 Methods of diagnosing endometrial carcinoma    43 
 






Table 15 Relationship between abnormal cervical cytology and type of  
endometrial carcinoma       44 
 
Table 16 Primary mode of non-surgical therapy     45 
 
Table 17 Peri operative parameters of women having primary surgical treatment 46 
 
Table 18 Perioperative variables based on body mass index    47 
 
Table 19 Complications following different surgical procedures  47  
 
Table 20 Number of complications based on BMI     48 
 
Table 21 Post-surgical management of women with endometrial carcinoma  49 
 
Table 22A Incompletely staged endometrial carcinoma     50 
Table 22B Distribution of histological subtypes by stage        51 
 
Table 23 Demographic profile of endometrial recurrence    52 
 
Table 24 Histological type at diagnosis and recurrence of endometrial  
carcinomas following treatment      52 
 
Table 25 Initial treatment of endometrial carcinomas that recurred   53 
 
Table 26 Cytology, histology and staging results of patients with endometrial  
carcinoma recurrence        54 
 
List of Figures 
 








Table of contents 
 
Declaration           ii  
Acknowledgements         iii  
Glossary          iv 
List of tables          v 
List of figures         vi 
Table of contents         vii 
Abstract          x 
 
Chapter 1: Introduction and literature survey    
 
1.1   Background         1 
1.2   Incidence         1 
1.3   Staging and classification of endometrial cancer 4 
1.4   Two main types of endometrial adenocarcinoma    7 
1.5   Predisposing factors for endometrial carcinoma    8 
1.6   Protective factors against endometrial carcinoma    13 
1.7   Phenotypic characteristics       15 
1.8   Method of evaluating the uterus      15 
1.9   Pre treatment evaluation       21 
1.10 Management of women with endometrial carcinoma   22 
1.11 Management options in endometrial cancer recurrence                        26 
1.12 Special clinical situations       30 
1.13 Posttreatment surveillance       31 
1.14 Survival rates          32 
1.15 Rationale 32 
1.16 Aim 33 







Chapter 2: Methodology        
 
2.1  Study design and location of study      34 
2.2  Materials and methods       34 
2.3  Statistical analysis        36 
2.4  Ethical considerations        36  
 
Chapter 3: Results         
  
3.1   Introduction         37  
3.2   Demographics and clinical characteristics     37 
3.3   Histopathological results at diagnosis     40 
3.4   Histopathological results in different race groups    40 
3.5   Predisposing factors affecting endometrial carcinoma   41 
3.6   Methods of diagnosing endometrial carcinoma    43 
3.7   Cervical Papanicolaou Smear results     43 
3.8   Treatment of endometrial adenocarcinoma    44 
3.9   Perioperative variables based on body mass index   47 
3.10 Complications following surgical procedures    47  
3.11 Relationship between complications and BMI    48 
3.12 Post-surgical management of women with endometrial carcinoma 49 
3.13 Staging of endometrial adenocarcinoma     50 
3.14 Recurrence details        52 
 
Chapter 4: Discussion        
 
4.1  Discussion         55 
4.2  Limitations         61 
 
 





References         63 
Annexures  
       
Annexure 1:  Data sheet        77 
Annexure 2:  Biomedical Research Ethics Committee approval  78 
Annexure 3:  Post Graduate Office approval     79 
Annexure 4:  Inkosi Albert Luthuli Central Hospital approval   80 


































Endometrial carcinoma is the second most common gynaecological cancer and the sixth 
most common cancer occurring in women. A significant number of women in South Africa 
are diagnosed with the disease each year. The National Cancer Registry of South Africa 
(2010) reported that 1 082 women were diagnosed with endometrial cancer. Endometrial 
cancer accounted for 3.64% of all cancers diagnosed in women compared to cervical cancer 




To determine the clinical profile and management of women treated for endometrial 




Retrospective chart review of women diagnosed with endometrial carcinoma over a 6-year 
period.  Eligible women were identified from a clinical database (all the records in the study 
site).  All relevant variables were recorded onto a structured data sheet which included race, 
age, age at menarche, age at menopause, obesity (BMI), parity, PCOS, hypertension, 
diabetes mellitus, HIV status, tamoxifen use, familial predisposition (Lynch syndrome), 
history of breast cancer, history of combined oral contraceptive use, postmenopausal 
bleeding, mode of histological diagnosis, FIGO staging, histological subtype, radiation 
therapy to the pelvis, management and postoperative complications.  Data was electronically 









Two hundred women during the study period of 6 years were diagnosed with endometrial 
carcinoma. The mean ± SD age at presentation of endometrial carcinoma was 63.8 ± 9.4.  
The main presenting complaint was postmenopausal bleeding (n = 187; 93.5%).  Age and 
obesity were the most significant predisposing factors.   
 
In our study 95 (47.5%) of endometrial carcinomas were diagnosed in Indian women and 92 
(46%) in black women. One hundred and eighty seven (93.5%) of the patients were HIV 
negative. One hundred and eighty seven (93.5%) patients were postmenopausal. Thirty two 
(16%) patients were nulliparous. Hypertension was found in 108 (54%) patients and 52 
(26%) presented with both hypertension and diabetes mellitus.  One hundred and eighty 
seven (93%) patients diagnosed with endometrial carcinoma were above fifty years of age 
and only thirteen (7%) were below fifty years of age. The mean ± SD endometrial thickness 
was 22.1 ± 5.9mm. Eighty-eight (44%) patients with endometrial carcinoma had an abnormal 
Pap smear result; however none detected the presence of abnormal endometrial cells. The 
profile of women with endometrial carcinoma showed that 13 (6.5%) had a normal BMI,89 
(44.5%) were overweight and 97 (48.5%) were obese. 
 
In 193 (96.5%) women, endometrial cancer was diagnosed using a Pipelle biopsy, and 7 
(3.5%) were diagnosed by DD&C.  One hundred and forty seven (73.5%) endometrial 
carcinomas identified in our study were of the endometrioid subtype and the remaining 53 
(26%) comprised serous carcinoma, clear cell carcinoma and carcinosarcoma. Eighty two 
(86%) Indian patients diagnosed with endometrial carcinoma presented with an endometrioid 
subtype, whereas the endometrioid subtype was observed in 54 (58.7%) black women.  
Twenty three (25%) black patients diagnosed with endometrial carcinoma had 
carcinosarcoma, whereas that was found in 7 (7.4%) Indian women. 
 
Surgery was performed as the primary treatment in 171 (85.5%) patients. One hundred and 
fifty (88.3%) of the 171 patients received adjuvant therapy following surgery.There was a 
significant association between BMI (obese 31% vs. normal 3%) and perioperative 
complications (p < 0.001).  Twenty (11.7%) patients had perioperative complications. Eight 





All patients reviewed at the combined gynaecology / oncology clinic at IALCH are scheduled 
for routine follow up. It is unknown how many patients were lost to follow up. Twenty eight 
(14%) patients had recurrent malignancy. Carcinosarcoma (n = 5; 15.6%) and endometrioid 




The results of the current study indicate that although endometrial carcinoma was more 
frequent among women who were older; especially after menopause, it may also occur in 
younger women in the premenopausal age group. Advancing age and obesity were the two 
important predisposing factors for endometrial carcinoma. In addition an increased BMI was 
associated with an increased proportion of post-operative complications.  
 
In African women, 58% of women diagnosed with endometrial carcinoma had the 
endometrioid subtype and 25% had carcinosarcoma. In Indian women, 86% of women 
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CHAPTER 1:  




Endometrial carcinoma is a gynaecological malignancy that arises from the endometrium. 
Worldwide it is the second most common gynaecological malignancy. (1)The South African 
National Cancer Registry (2010) reported that endometrial carcinoma was the second most 





Incidences, however, show a wide variation among different regions in industrialised 
countries. In industrialised nations the overall lifetime risk of endometrial carcinoma is 1.6%. 
(2) This is in comparison to a 0.6% overall incidence seen in poorer socio-economic 
countries. (2) In the United States of America and the United Kingdom, it was found to be the 
fourth most common cancer in women. The lifetime risk was found to be 3.9 and 2 – 3%, 
respectively. (3) Advancing age was identified as a risk factor for the development of 
endometrial cancer. (4,5) Most women diagnosed with endometrial carcinoma are 
postmenopausal. However, 25% are premenopausal and 4% are less than 40 years of age 
at the time of diagnosis. (6) Women older than 70 years have a 1 in 81 risk for developing 
endometrial carcinoma compared to the risk of 1 in 1 423 found in women younger than 40 
years of age. (5, 7) In a rare case report a 13-year-old Korean girl was diagnosed with grade 
II endometrial adenocarcinoma after she presented with abnormal uterine bleeding. (8) 
There has been an international increase in the incidence of endometrial carcinoma 
attributed both to the increase in the ageing female population and the rise in obesity. (9) In 
South Africa, uterine carcinoma is the 3rd most common gynaecological carcinoma and is 
ranked 3rd in Asians (7.1%), 5th in Africans (4.4%), 6th in Coloureds (3.48%) and 7th among 
Caucasian (2.1%) women. (10) The lifetime risk of endometrial carcinoma among the 
subpopulations in South Africa is shown in Table 1. 
2 | P a g e  
 
Table 1: Lifetime risk of endometrial carcinoma among the different 
racial groups in South Africa (2010) (10) 














A white female in the USA has a lifetime risk of 2.88% for endometrial cancer with a mortality 
rate of 3.9 / 100 000, compared to a black female who has a 1.69% lifetime risk and a 
mortality rate of 7.2 per 100 000. (11) 
Among the South African population the age standardised incidence ratios (ASIR) of 
endometrial carcinoma are 4.26, 4.86, 6.31, and 6.64 per 100 000 population in Blacks, 
Asians, Whites and Coloureds, respectively. (12) In the United States, the figures for White, 
Black, Asian and Hispanic women were 24.8, 20.9, 18.2 and 15.9 per 100 000 population, 
respectively. (13) Similarly in the UK the figures for White, Asian and Black women were 
16.9 - 17.7, 10.7 - 18.0 and 13.7 - 23.6 per 100 000 population, respectively. (14) Table 2 
lists the age standardised incidence ratios of three different countries. 
 
Table 2: Age standardised incidence ratios (ASIR) of endometrial 











4.26 / 100 000 
4.86 / 100 000 
6.31 / 100 000 
6.64 / 100 000 








24.8 / 100 000 
20.9 / 100 000 
18.2 / 100 000 









16.9 – 17.7 / 100 000 
10.7 – 18.0 / 100 000 
13.7 – 23.6 / 100 000 
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Uterine cancer may present with abnormal uterine bleeding or an abnormal vaginal 
discharge, and pelvic pain or pressure. (15) The commonest clinical presentation is that of 
abnormal uterine bleeding. (16) This refers to either intermenstrual or heavy menstrual 
bleeding. (16) Any amount of vaginal bleeding is abnormal in the postmenopausal female 
and requires investigation. (16, 17) Postmenopausal bleeding refers to any vaginal bleeding 
(even a single drop) that occurs more than 12 months after the cessation of menses. (16, 18, 
19) 
 
Diagnostic evaluation for endometrial carcinoma may be recommended in a woman who 
presents with abnormal uterine bleeding. Methods of endometrial sampling include an 
endometrial biopsy and hysteroscopy. (18, 20) These investigations involve taking a sample 
of the endometrium, which is then examined for the presence of abnormal or dysplastic cells. 
A transvaginal ultrasound is an essential component of the evaluation in a woman 
presenting with abnormal uterine bleeding.  
 
Endometrial cancer is staged using the FIGO system once a tissue diagnosis has been 
made. (16, 21–23) The basis for staging includes the depth of uterine muscle infiltration by 
the cancer, and spread to other organs. (21) This can be determined on a comprehensive 
physical examination and supportive diagnostic imaging. (16) Stages range from I where the 
malignancy has not invaded beyond the uterine lining, to stage IV where it has spread to 
distant organs. (16) Lower stage endometrial carcinomas are usually considered to be less 
aggressive and require less treatment compared to higher grade malignancies. (16) 
 
A laparotomy is usually performed as part of staging endometrial carcinomas. A TAH with 
BSO, para-aortic and pelvic lymphadenectomy and peritoneal washings offers a therapeutic 
benefit in addition to aiding the staging of the disease. (16, 23) During laparotomy the para-
aortic and pelvic lymph nodes are examined and a lymphadenectomy is performed, as the 
lymph nodes is one the first places endometrial cancer spreads to. (16) Peritoneal washings 
and any other abnormal pelvic or abdominal tissue are collected for cytological and 
histological evaluation. (16) Cytoreductive surgery may be performed if there is evidence of 
metastases. (23) 
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A risk assessment is performed to aid the planning of treatment of endometrial carcinoma. 
This assessment is based on the likelihood of recurrence of the malignancy. The following 
factors are taken into consideration: (16) 
 The stage of the cancer, as determined at laparotomy 
 The grade of the tumour on histology 
 The histological subtype of the tumour 
 
1.3 Staging and classification of endometrial carcinoma  
 
Endometrial carcinoma is surgically staged according to the Joint International Federation of 
Gynaecology and Obstetrics (FIGO) / TNM classification system(2009): (21) 
FIGO ENDOMETRIAL CANCER STAGING CRITERIA (2009) 
 
 IA:       Tumour confined to the uterus with no or < 50% myometrial invasion 
 IB:       Tumour confined to the uterus with ≥ 50% of the myometrium 
 II:      Cervical stromal invasion but not beyond the uterus 
 IIIA:    Tumour invades the serosa or adnexa 
 IIIB:      Vaginal and / or parametrial involvement  
 IIIC1:   Pelvic node involvement 
 IIIC2:   Para-aortic lymph node involvement 
 IVA : Tumour invasion to bladder and / or bowel mucosa 
 IVB :     Distant metastases – including abdominal metastases and / or inguinal lymph  
nodes 
FIGO ENDOMETRIAL CANCER STAGING CRITERIA (1988) 
 IA:  Tumour limited to the endometrium 
 IB: Invasion to less than 50% of the myometrium 
 IC: Invasion to more than 50% of the myometrium 
 IIA: Endocervical glandular involvement only 
 IIB: Cervical stromal invasion 
 IIIA: Adnexal or serosal involvement or positive peritoneal cytology 
 IIIB: Vaginal metastases  
 IIIC:  Metastases to pelvic or para-aortic lymph nodes 
 IVA: Bowel or bladder mucosal invasion 
 IVB: Distant metastases – includes omental and inguinal metastases 
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1.3.1  Histopathological grading of endometrial carcinoma (24) 
 
 Grade 1: Adenocarcinoma having 5% or less non-squamous or non-solid growth 
 Grade 2: Adenocarcinoma having 6 - 50% of solid growth 




1.3.2  Classification and histopathological features of endometrial    
carcinoma 
 
Endometrial carcinoma develops from normal epithelium and is preceded by pre-
carcinomatous hyperplastic cells with mild to moderate architectural abnormality. The 
histological presentation of this pre-carcinomatous hyperplastic stage is often typical.  
Endometrial hyperplasia was previously classified into 4 subtypes: (24–26) 
(1) Simple hyperplasia without atypical cells 
(2) Simple hyperplasia with atypical cells 
(3) Complex hyperplasia without atypical cells 
(4) Complex hyperplasia with atypical cells 
 
Normally simple and complex hyperplasia’s are not significant pre-carcinomatous lesions 
and less than 10% progress to invasive carcinoma. However, when atypical cells are present 
the risk increases to 10 – 20%. (27) The progression to carcinoma occurs in 1% and 3% of 
patients with simple and complex hyperplasia without atypical cells, respectively, compared 
to 8% and 29% of patients with simple and complex hyperplasia with atypical cells. (28) 
Within ten years, 8 – 30% of patients with atypical endometrial hyperplasia’s develop into 
endometrial cancer, whereas only 1 – 3% of non-atypical hyperplasia undergoes this 
progression. (28, 29) 
In 2014 the WHO issued a simplified classification as the previous and parallel 
classifications caused confusion among clinicians and led to incorrect treatment. (26) The 
new classification only recognises two categories: (26) 
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 Hyperplasia without atypia 
 Atypical hyperplasia / endometrioid intraepithelial hyperplasia 
 
The endometrial intraepithelial neoplasia (EIN) is a system used to classify precancerous 
lesions of the endometrium. (30) It shows high interobserver reproducibility. Epithelial 
crowding in premalignant lesions displaces endometrial stroma until it reaches a volume of 
less than 50% of the total tissue. Stromal volume can be measured using a D-score. (30–32) 
 
The majority of the malignant tumours of the endometrium are well-differentiated 
adenocarcinomas. These include:(33) 
 
 Endometrioid (75%)  
o Ciliated adenocarcinoma 
o Secretory adenocarcinoma 
o Papillary and villoglandular adenocarcinomas  
o Adenocarcinoma with squamous differentiation 
 Adenoacanthoma 
 Adenosquamous cells  
 Mixed, defined as two carcinomatous cell types, with the smaller component making 
up at least 10% of the total (10%) 
 Uterine papillary serous (<10%) 
 Clear cell(4%) 
 Carcinosarcoma (3%) 
 Mucinous (1%) 
 Squamous cell (<1%) 
 Undifferentiated (<1%) 
 
Endometrial carcinoma invades the myometrium at an early stage and remains confined to 
the uterus until the later stages of the disease. (34) Based on histology and clinical 
assessment there are two main types of endometrial adenocarcinoma. 
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1.4 Two main types of endometrial adenocarcinoma 
 
Type I (endometrioid adenocarcinoma of the endometrial epithelium), is a low grade 
adenocarcinoma confined to the uterus with minimal invasion, is oestrogen dependant, and it 
occurs in younger or perimenopausal women. (5) Approximately 85% of endometrial 
carcinomas are type I. (5) They occur in women with an increased BMI and is usually 
preceded by complex atypical hyperplasia. (5, 35, 36) Owing to their early diagnosis 
secondary to postmenopausal bleeding and having more benign histological features, they 
have a good prognosis. 
Type II (serous or clear cell) endometrial tumours are aggressive, non-oestrogen dependent 
and non-endometrioid. (5) They typically occur in thin, older patients who have an atrophic 
endometrium. (5, 35, 37) They typically present with high-grade serous or clear cell 
histological subtypes and are associated with early metastases. (5, 8, 35) Fifty percent of 
patients presenting with endometrial cancer relapse, occur in patients diagnosed with type II 
tumours. (5, 38) Type II endometrial carcinomas develop in older patients, are not hormone-
dependent and are responsible for most of the recurrences and deaths associated with 
endometrial carcinoma. (5) 
 
The two tumour types display distinct molecular variation. Molecular characteristics of type I 
endometrial tumours include K-RAS, PTEN, microsatellite instability (MSI),β-catenin 
mutations and large quantities of progesterone receptors. (5, 35) Type II endometrial 
tumours show p53 mutations and HER2 / neu amplification. (5, 38, 39) Table 3 summarises 
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Table 3: Differences between type I and type II endometrial 
carcinomas 









 Hormone dependency 
 
 Tumour development 
 
 Stage at diagnosis 
 
 Genetic factors 
 
 Clinical course 












I or II 
 
PTEN, MSI, β-catenin 
 
Indolent (good prognosis) 
 












III or IV 
 
HER2 / neu, p53 
 
Aggressive (poor prognosis) 
 
Although endometrioid adenocarcinoma originates from the atypical hyperplastic cells, some 
of these carcinomas arise from an atrophic endometrium. Uterine serous papillary carcinoma 
is an uncommon form of endometrial cancer. It does not develop from endometrial 
hyperplasia and is not hormone sensitive. It does however arise in the background of 
endometrial atrophy.(34, 40) 
 
1.5 Predisposing factors for endometrial carcinoma 
 
The following factors may increase a woman’s risk of developing uterine carcinoma: obesity, 
diabetes, hypertension, unrestricted oestrogen, and tamoxifen use for > 5 years. The risk of 
unrestricted oestrogen is potentially associated with obesity, polycystic ovarian syndrome, 
nulliparity, late menopause, oestrogen-producing tumours, anovulation and oestrogen 
monotherapy. (23, 41) 
 
Inherited factors contribute to endometrial cancer in as many as 10% of cases. 
Approximately half of these cases occur in families with a hereditary predisposition for 
nonpolyposis colorectal carcinoma (Lynch syndrome) 
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Heredity factors contribute to endometrial carcinoma in as many as 10% of cases, with 
approximately half of these cases occurring in families with hereditary nonpolyposis 
colorectal carcinoma (Lynch syndrome) who have a marked increase in risk of endometrial 
cancer compared to that of the general population. (23, 42) 
 
1.5.1  Age 
 
Endometrial cancer is more common in older, peri-menopausal or postmenopausal women, 
with mean age at diagnosis being in the early 60s. (5, 43) Only 25% of cases occur in 
premenopausal women, and only 5 – 10% of these women are less than 40 years of age. (5, 
44) There is only a 0.05% overall probability of developing endometrial cancer between birth 
and the age of 39 years. (5, 45) Women younger than 50 years with endometrial cancer 






1.5.2  Exposure to oestrogen 
 
Risk is increased with increased duration of use and dose. 
 
1.5.2.1 Exogenous oestrogen 
 Hormone replacement without progestin 
 Tamoxifen use for breast cancer 
 
Oestrogen therapy in the postmenopausal woman offers a number of short- and long-term 
benefits as it improves hot flushes, vaginal dryness and helps to maintain bone mineral 
density. (46)Unopposed oestrogen use increases a woman’s risk for both endometrial 
hyperplasia and carcinoma. (46–48) Five years of oral contraceptive use may halve the risk 
of developing endometrial carcinoma. (5, 49) The concomitant administration of progestins 
significantly decreases the risk of developing endometrial hyperplasia and carcinoma. (46, 
50–52) The risk of developing endometrial cancer from oestrogen therapy is dose 
dependent. (5, 53, 54) Both case control and prospective studies demonstrated an increased 
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incidence of endometrial carcinoma associated with oestrogen therapy, the relative risk 
ranging from 3.1 to 15. (46, 55, 56) 
 
1.5.2.2 Endogenous oestrogen 
 Obesity (overweight and obesity) 




 Early menarche (< 12 years) / Late menopause (> 52 years) 
 Oestrogen-producing tumours 
 Comorbid disease (diabetes mellitus and hypertension) 
 Genetic factors 
The risk of developing endometrial carcinoma from endogenous oestrogen is related to the 
conversion of adrenal precursors to oestrone and oestradiol by adipose cells in the body. 
(46) A postmenopausal woman’s risk of developing endometrial carcinoma is correlated with 
both higher circulating oestrogen and androgen levels, and lower sex hormone binding 
globulin levels. (46, 62– 66) 
 
1.5.3  Tamoxifen use 
 
Tamoxifen is a competitive inhibitor of oestrogen. (46)  It binds to oestrogen receptors. It is a 
weak oestrogen, as it only has partial agonist activity. (46) It suppresses the growth of breast 
tissue but stimulates the endometrial lining. (46, 57) The risk of developing endometrial 
carcinoma from tamoxifen increases not only with a longer duration of use, but also with a 
higher cumulative dose. (5, 58, 59) Tamoxifen use has also been associated with benign 
endometrial pathology. (5, 60, 61) 
 
1.5.4  Obesity 
 
It is estimated that obesity increases the risk for endometrial cancer by 300 – 400%. (67) 
While overweight women have double the risk of developing endometrial cancer, obese 
women have four to five times the risk compared to normal weight women. (5, 68) 
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Women who have a BMI of > 32kg/ m2 are four times more likely to develop endometrial 
cancer when compared to women with a BMI < 23kg/m2, while obese women (BMI > 
35kg/m2) have six times the risk. (5, 69) For each increase of 5kg/m2 in BMI, the risk of 
developing endometrial cancer is significantly increased. (5, 70) A higher BMI is also a risk 
factor for endometrial carcinoma in women under 45 years of age. (46, 71) 
It is postulated that the peripheral conversion of androstenedione to oestrone and the 
aromatisation of androgens to oestradiol in the adipose tissue of overweight and obese 
women forms the basis for an increased risk of developing endometrial cancer, as these 
women have high levels of endogenous oestrogen. (46) Other postulated mechanisms 
include lower circulating levels of SHBG, alterations in the concentration of insulin like 
growth factor, and insulin resistance. (46, 72, 73) 
 
1.5.5  Chronic anovulation (PCOS) 
 
A recent case control study demonstrated that women under 50 years of age with PCOS 
have a four times higher risk of developing endometrial cancer. (9, 75) Constant oestrogenic 
stimulation of the endometrium in women with PCOS may lead to endometrial hyperplasia or 
endometrial carcinoma. (42, 46, 70) Endometrial carcinoma is associated with PCOS in the 
majority of young patients with up to 30% having concomitant PCOS. (43, 46, 76) 
1.5.6  Nulliparity 
 
The risk of endometrial cancer is inversely related to parity (46, 77–79) as nulliparous 
women have a 2 to 3 times higher risk of endometrial cancer. (46, 52) Nulliparity, however, is 
not an independent risk factor and the association most likely lies in the high number of 
anovulatory menstrual cycles in sub-fertile or infertile women. (46) Each child decreases a 
woman’s risk of endometrial cancer. (80) 
 
1.5.7  Early menarche and late menopause 
 
Early menarche (younger than 12years) and late menopause (older than 55 years) are risk 
factors for endometrial cancer, although late menopause is a less consistent risk. (46, 69, 
78, 81, 82) The underlying mechanism is thought to be prolonged oestrogen stimulation in 
the absence of protection by progesterone. (46) 
12 | P a g e  
 
1.5.8  Oestrogen-producing tumours 
 
About 6 - 10% of patients with oestrogen-producing tumours will develop endometrial 
cancer. (5, 83) 
 
1.5.9  Breast cancer 
 
Partly because of common risk factors including obesity and nulliparity, a woman with a 
personal history of breast cancer is at a higher (2 to 3 fold) risk for developing endometrial 
cancer. (46) It is unclear whether the BRCA 1 gene has a role in the development of 
endometrial cancer. (46, 84, 85) Some studies suggest that only BRCA 1 carriers using 
tamoxifen have a higher risk of endometrial cancer. (86) 
Postmenopausal patients receiving tamoxifen therapy are at a higher risk of developing 
endometrial carcinoma when compared to premenopausal women. (87–89)Breast cancer 
patients receiving adjuvant tamoxifen treatment have a 4 to 14 fold higher risk of developing 
endometrial carcinoma compared to healthy women who do not use tamoxifen. (46, 57, 90, 
91) A prospective study by Cohen et.al found that symptomatic tamoxifen-treated breast 
cancer patients had a 22% incidence of endometrial carcinoma compared to a 1% incidence 
in asymptomatic tamoxifen-treated patients. (91, 92) 
A large meta-analysis that included more than 20 000 women with breast cancer who were 
treated with tamoxifen for > 5 years found that these patients had a higher risk (rate ratio 
2.40) of developing endometrial cancer, compared to women who did not receive tamoxifen. 
The risk, however, was only found to be significant in patients older than 55 years. (87, 89) 
 
In patients on tamoxifen endometrial surveillance may be done with transvaginal ultrasound 
and regular endometrial sampling. (93) However, ACOG does not recommend routine 
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1.5.10   Diabetes mellitus and hypertension 
 
Women who suffer from diabetes mellitus and / or hypertension have an increased risk of 
developing endometrial cancer. (5, 67, 95) Type 2 diabetes mellitus is a risk factor for 
endometrial carcinoma, even when adjusted for confounding factors such as obesity, and it 
confers a higher risk than type 1 diabetes mellitus. (5, 52, 96, 97)Diets high in carbohydrates 
are associated with hyperinsulinemia, insulin resistance and elevated levels of insulin like 
growth factor, all of which may contribute to endometrial proliferation and subsequent 
endometrial cancer. (98, 99) 
 
1.5.11  Family predisposition and genetics 
 
A family history confers a higher risk of endometrial cancer. (33) It has been suggested that 
there is a tendency toward isolated endometrial cancer in women with a first degree family 
history, but no consistent causative gene could be identified to date. (46, 100) Lynch 
syndrome is a familial condition associated with endometrial carcinoma, conferring a lifetime 
risk of 27 – 71% compared to 3% in the general female population. (9, 46) 
 
 
1.6  Protective factors against endometrial carcinoma 
 
 Combined oral contraceptives  
 Parity 
 Physical activity 
 Lactation    
 Smoking 
 
1.6.1  Combined oral contraceptives 
Combined oral contraceptives decrease the risk of endometrial cancer more, the longer they 
are used: 56% after 4 years, 67% after 8 years, and 72% after 12 years. (102, 103) This 
protective benefit lasts up to 15 years after cessation of COCs. (102, 103) 
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The protective mechanism of COCs is most likely related to the progestin component, as it 
suppresses endometrial proliferation. (46) A woman who has used COCs at some point in 
her life has a lower (0.5) relative risk of endometrial carcinoma. This protection occurs if a 
woman used COCs for at least 12 months, and is most noticeable in nulliparous women. 
(101) 
  
1.6.2  Parity 
Grand multiparity is a protective factor against endometrial cancer. Having one child 
decreases the individuals risk by 35%. (46) 
 
1.6.3  Physical activity 
 
It is unclear whether occupational or recreational physical activity offers protection against 
endometrial carcinoma. (101), (108–111) Risk reduction may be due to the associated 
decrease in obesity, favourable immune system changes and endogenous sexual and 
metabolic hormone levels and growth factor. (46, 112) 
Approximately 50% of uterine carcinomas occur in women with these particular risk factors. 
Interestingly risk factors such as obesity, menstrual irregularities and nulliparity / infertility 
seem to be predominant in women younger than 40 years compared to older women where 
factors like hypertension and diabetes seem to be more common.  
 
1.6.4  Lactation 
Breastfeeding for more than 18 months may decrease the risk of endometrial cancer by up 
to 23%. 
 
1.6.5  Smoking 
 
There is an inverse relationship between cigarette smoking and endometrial cancer with a 
relative risk of 0.5%. (5, 69, 104–107) The effect is related to weight, as heavier women 
have the greatest risk reduction. (101) 
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1.7 Phenotypic characteristics 
 
The existence of two pathogenic types of endometrial cancer, based on phenotypic 





 Signs of hyperestrogenism 
 History of uterine bleeding 
 Infertility  
 Late onset of menopause  
 Hyperplasia of the ovary and the endometrium 
 Nulliparity 
 
These patients tend to have well differentiated, superficially invasive endometrial cancer 
which is sensitive to progesterone.  They tend to have a favourable prognosis, and 




None of the above characteristics are present in these women. Tumours are poorly 
differentiated, associated with deep myometrial invasion, have a high rate of nodal and 
distant metastases, have a decreased sensitivity toprogestins, and have a poor prognosis.  
 
1.8 Methods of evaluating the endometrium 
 
Evaluation of the endometrium is an important component in the diagnostic evaluation of 
women suspected of having endometrial cancer or in women where a premalignant 
endometrial lesion is suspected. 
16 | P a g e  
 
Evaluation methods are classified as either invasive or non-invasive. An endometrial biopsy 
or dilatation and curettage is commonly performed to diagnose endometrial cancer by 
obtaining a tissue sample for histology. (103) 
 
1.8.1 Dilation and curettage 
 
Dilation and curettage is used less frequently than endometrial biopsy, but it is still the gold 
standard for evaluation of the endometrium in the following clinical circumstances (113): 
 
 When a patient is unable to tolerate an endometrial biopsy (e.g. due to excessive 
anxiety or pain) 
 After a non-diagnostic office biopsy in women with an increased risk of endometrial 
carcinoma 
 Following benign histology from an endometrial biopsy in a woman with persistent or 
recurrent abnormal uterine bleeding 
 When there is insufficient tissue for adequate analysis following an office biopsy 





Disadvantages of Dilatation and Curettage 
 
 The entire endometrial cavity is not sampled. Only 60% of the endometrial cavity is 
sampled (113–115) 
 The fractional curettage used to determine cervical involvement is inaccurate as it 
has significant false positive and false negative rates (67, 113, 116) 
 
 
1.8.2 Endometrial biopsy 
The Pipelle is the most extensively used device for endometrial sampling as it compares 
favourably to, and offers many advantages over standard dilation and curettage, and it has 
an excellent correlation for diagnosing endometrial carcinoma. (113, 117–119) 




 Less traumatic than hysteroscopy or dilatation and curettage 
 Little or no anaesthesia needed 
 Rapid, easy and relatively cheap method to diagnose endometrial carcinoma. 
However, it has limitations in that it might be inaccurate in diagnosing the true tumour 
grade in the uterus (120) 
 
Thirty percent of (preoperative) grade I tumours are upgraded to a higher grade upon 
examining the postoperative sample. (121) Upgrading, however, is less likely to occur after 
dilation and curettage than Pipelle biopsy. (119) Renaud and Le found that only 8.7% of 
tumours diagnosed by dilation and curettage were upgraded, while 17.4% diagnosed via 




Hysteroscopy is primarily used for the detection of polyps and other endometrial lesions in 
patients with persistent or recurrent abnormal uterine bleeding with benign endometrial 
sampling or deficient sampling by dilation and curettage or endometrial biopsy, as this 
method allows for direct visualisation of the endocervical canal and the endometrial cavity. 
(122) A number of studies have demonstrated that hysteroscopy can assist in the detection 





 Expensive (113) 
 Only the gross anatomy of the endometrium is evaluated, which is often not 
indicative of cancer. It is rarely used, unless in circumstances where an endometrial 
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1.8.4 Transvaginal ultrasound 
 
Transvaginal ultrasound is widely used to evaluate endometrial thickness in patients 
presenting with postmenopausal bleeding. (126)It is a non-invasive method used to evaluate 
for endometrial hyperplasia or cancer in women with postmenopausal bleeding if the 
endometrium is homogenous, and is increasingly used to assist in the diagnosis of 
endometrial carcinoma. (9, 127) 
 
An endometrial thickness of < 5mm is associated with a low risk of endometrial cancer. The 
ratio of malignant to benign disease increases as the endometrial thickness approaches 
20mm. The sensitivity and specificity of transvaginal ultrasound for the detection of 
endometrial carcinoma at a threshold of 5mm thickness were 96% and 61%, respectively. 
(128) As a result of there being no standard threshold for endometrial thickness in 
premenopausal women, the role of transvaginal ultrasound in diagnosing endometrial cancer 
has not been established. 
 
Transvaginal ultrasound is not a  useful screening tool for excluding endometrial hyperplasia 
or cancer in patients on oestrogen therapy, irrespective of whether it is unopposed, or given 
with cyclic progesterone. Women receiving tamoxifen therapy, both for the prevention and 
treatment of breast cancer, commonly have thickened endometrial stripes.  There is no well-
defined cut off for normal vs. pathological endometrial thickness in this category of patients. 
The criteria for a thickened endometrium necessitating intervention in postmenopausal 
women without any uterine bleeding have not been established.  It is recommended that the 
clinician perform sampling of the endometrium in postmenopausal women without any 
uterine bleeding where the endometrial thickness is greater than 11mm. (129) 
 
In asymptomatic premenopausal women endometrial thickening alone is not a justifiable 
indication for biopsy and endometrial sampling. Endometrial evaluation is based on a 
combination of factors which includes cervical cytology results showing glandular 
abnormalities or endometrial cells. 
 
 A number of studies reported that endometrial thickness ≤ 4 – 5mm in patients with 
postmenopausal bleeding reliably excluded endometrial cancer. (118, 130–132) Several 
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studies, however, found that endometrial cancer may occur even when the endometrial 
thickness on transvaginal ultrasound measures < 5mm. (126, 133–135) 
Transvaginal ultrasound as an isolated screening test is inconclusive, and must be combined 
with another method, e.g. endometrial biopsy. (103) 
 
Endometrial thickness measurements in postmenopausal bleeding in 
different conditions 
 
 History of postmenopausal bleeding (and not on HRT / tamoxifen): 
o Suggested upper limit of normal is < 5mm (103, 128, 131, 132) 
o Risk of carcinoma (± 7%) if endometrium is > 5mm and 0.07% if endometrium 
is < 5mm (136) 
 
 No history of postmenopausal bleeding  (and not on HRT / tamoxifen): 
o An acceptable range of endometrial thickness is less well established in this 
group; cut-off values of 8 or 11mm have been suggested.  (129) 
 
 On hormonal therapy: upper limit is 8 - 15mm (137) 
 
 On tamoxifen:< 6mm (138) (about 50% of those receiving tamoxifen have been 
reported to have a thickness of > 8 mm (139) 
 
Endometrial thickness measurement in a patient taking tamoxifen 
 
ACOG recommendations for endometrial cancer surveillance in women taking tamoxifen 
are(140): 
 
 Postmenopausal women without postmenopausal bleeding should not undergo 
routine ultrasound examination or endometrial biopsy 
 Endometrial evaluation, including biopsy, should be performed in patients presenting 
with abnormal uterine bleeding 
 The following investigations are indicated in a premenopausal woman taking 
tamoxifen and presenting with abnormal uterine bleeding: hysteroscopy, 
hysterosonography, and biopsy if the aetiology remains unclear 
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 Tamoxifen leads to endometrial thickening in the absence of malignancy as it causes 
enlargement of subendometrial glands. Endometrial thickening alone should not 
prompt evaluation in a patient taking tamoxifen. 
 
Asymptomatic women with endometrial fluid on ultrasound 
 
The incidental finding of endometrial fluid in asymptomatic women with an endometrial 
thickness of < 3mm is unlikely due to endometrial hyperplasia or malignancy. A biopsy is 
indicated if the endometrial thickness is > 3mm as these women have an increased risk of 




A reliable transvaginal ultrasound evaluation of endometrial thickness and texture may be 
hampered by an axial uterus, marked obesity, coexisting myomas and previous uterine 
surgery. (128, 142) 
If a thin, distinct endometrial stripe in a bleeding, postmenopausal woman cannot be 
identified, an alternative method must be used. It is important to exclude endometrial fluid, if 
present, when measuring endometrial thickness. (128) 
 
1.8.5 Other imaging studies 
 
Imaging studies are discussed in more detail under the heading of ‘Pre-treatment 
evaluation’. 
 
1.8.6 Infusion sonohysterography 
This technique is useful for better visualisation of anomalies and irregularities of the 
endometrial cavity. Liquid media is injected into the uterus prior to ultrasound examination. 
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1.9 Pre-treatment evaluation 
 
A comprehensive pelvic and general physical examination is required prior to commencing 
treatment for endometrial cancer. Clinical findings that should be noted include: Mobility and 
size of the uterus, presence of adnexal masses or ascites, and palpation for enlarged / 
pathological lymph nodes. (143, 193) Laboratory studies should be guided by the planned 
treatment modality, suspicion of metastases and patient comorbidities. Cervical cancer 
screening should be performed.(143) 
 
1.9.1 Tumour markers 
 
Serum CA – 125 may be a clinically useful marker to predict extra uterine spread of 
endometrial cancer. (143) 
Preoperative raised CA – 125 levels have been associated with higher staged disease, 
presence of a serous component, and myometrial invasion.  (194)One retrospective study 
found that a CA – 125 value of > 40units/ml has a 78% sensitivity and 81% specificity for 
nodal metastases. (143, 195) 
An optimal threshold value has not been established. (143, 196–200) Serum CA – 125 levels 
are usually higher in premenopausal than postmenopausal women. (143) 
 
1.9.2 Imaging studies 
 
Special pelvic and / or abdominal imaging is unnecessary in most patients as endometrial 
carcinoma is a surgically staged malignancy. (21, 24, 143) 
Compared to non-contrast enhanced MRI, CT, PET and ultrasound, contast enhanced MRI 
is the superior modality for detection of myometrial or cervical invasion, or lymph node 
spread. (143, 201–203) Studies have reported the sensitivity of contrast-enhanced MRI to 
detect myometrial invasion to be around 80 – 90%. (14, 143) Its sensitivity for cervical 
invasion is, however, more inconsistent ranging from 56 to 100%. As such a negative study 
cannot conclusively rule out local infiltration. (143) 
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Preoperative staging should include a chest X Ray and ultrasound of the abdomen to 
exclude lung and liver metastases, respectively. (93) 
Some authors are of the opinion that MRI should be standard practice in well-resourced 
settings, as part of the preoperative workup. (93) 
 
 
1.10 Management of women with endometrial carcinoma 
 
Surgery is the primary treatment modality for early stage endometrial cancer, followed by 
adjuvant therapy in selected cases. This includes radiation therapy with or without 
chemotherapy, based on stratification of patients into categories depending on their future 
recurrence risk. 
 
1.10.1 Surgical management 
 
Surgery alone may be curative in patients with low risk disease i.e. endometrioid histology, 
grade 1 or 2, confined to the endometrium and there are no risk factors for persistence or 
recurrence. (143) 
 
Total extra fascial hysterectomy with BSO, and aortic and pelvic lymphadenectomy has been 
the standard approach in patients who are medically fit for surgery and do not have obvious 
extrauterine disease. (21, 143) In addition, a complete staging laparotomy includes biopsies 
of any suspected metastases. Cytoreduction is done if there is intraoperative evidence of 
metastases.(143)The intraoperative assessment of lymph nodes is controversial and 
discussed in more detail below. At a minimum pelvic and para-aortic lymph nodes need to 
be palpated and enlarged or suspicious nodes excised. (143, 144) Gross intraoperative 
inspection of the uterine specimen by a pathologist to determine the depth of myometrial 
invasion has a 75% sensitivity and 92% specificity. (143, 145) The value of intraoperative 
frozen section is questionable. (146–149) Peritoneal fluid collection is not required in the 
2009 FIGO staging. (24) 
Laparoscopic, vaginal and robot assisted procedures are now also possible. (143) 
 
23 | P a g e  
 
Laparotomy vs. laparoscopy 
 
Laparoscopy for the staging and treatment of endometrial carcinoma is a feasible and safe 
surgical modality. (143, 150) It decreases the perioperative morbidity while its efficacy is 
comparable to that of laparotomy in women with early stage disease. (143, 151, 152) 
 
The Gynaecologic Oncology Group (GOG) published the results of the largest randomised 
control trial comparing laparoscopy to laparotomy in patients with newly diagnosed 
endometrial carcinoma.(150, 153) The study revealed the following(150): 
 
 The conversion rate from laparoscopy to laparotomy was 25% 
 The ability to retrieve pelvic lymph nodes and median pelvic nodes was similar 
 Para-aortic nodes were successfully retrieved in 94% of cases randomised to 
laparoscopy compared to 97% of those randomised to laparotomy 
 The detection of nodal disease was the same in both groups 
 The rate of postoperative complications, median blood loss and median length of 
hospital stay were significantly lower in patients randomised to laparoscopy 
 
A meta-analysis of four randomised control trials comparing laparoscopically assisted or total 
laparoscopic hysterectomy in women undergoing complete surgical staging for endometrial 
caracinoma found laparoscopic procedures to have the following benefits: It had fewer 
perioperative complications, decreased blood loss (267ml less), a shorter hospital stay (3 vs. 
4 days) and a faster return to normal activity (28 vs. 48 days). Operative time is, however, 
much longer (3.3 vs. 2.2 hours). (143, 154) 
 
Intraoperative lymph node assessment 
Endometrial carcinoma is a surgically staged malignancy. The results of two randomised 
trials comparing pelvic lymphadenectomy to no lymphadenectomy, demonstrated that 
lymphadenectomy improved surgical staging but did not result in improved survival (Panici et 
al., 2008; ASTEC Study Group, 2009).  There is general consensus that the value of 
lymphadenectomy in truly low risk cases is questionable.  The problem still lies in identifying 
these low risk cases using preoperative and intraoperative features. 
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Currently the only way to most accurately identify the presence of microscopic nodal disease 
is with a comprehensive pelvic and para-aortic lympadenectomy.  Lymphadenectomy is not 
therapeutic by itself, and the results of the lymphadenectomy must be used to guide 
decisions regarding adjuvant therapies (Leitao and Barakat, 2011). 
 
Extra uterine disease, and especially para-aortic and pelvic lymph node metastases, is an 
important prognostic factor for endometrial carcinoma. The approach to lymph node 
assessment is still a controversial topic, especially in patients presumed to have early stage 
disease. (143) The rate of nodal spread is dependent on both tumour grading and stage. It 
varies from 3 – 5% in patients with well-differentiated, superficially invasive tumours, to 20% 
in patients with poorly differentiated, deeply invasive cancers. (143, 155–157) 
 
The following factors indicate a high risk of lymph node involvement, and even patients 
presumed to have stage I disease may benefit from surgical resection of the lymph nodes: 
 Serous, clear cell or high grade histology 
 Myometrial invasion that is greater than 50% 
 Large tumours (> 2cm in diameter or filling the endometrial cavity) (143) 
The risk of lymph node involvement in patients with clinical stage I endometrial cancer, is 
summarised in the table below.  
 
Table 4: Risk of lymph node involvement in patients with clinical 
stage I disease(33, 158) 
Prognostic group Patient characteristics Risk of nodal 
involvement 
A Grade I tumours involving 
only endometrium 
< 5% 
No evidence of 
intraperitoneal spread 
B Grade II – III tumours 5 – 9% pelvic nodes 
 Invasion of < 50% of 
myometrium 
 No intraperitoneal spread 4% para-aortic nodes 
C Deep muscle invasion 20 – 60% pelvic nodes 
 High grade tumours 10 – 30% para-aortic nodes 
 Intraperitoneal spread 
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Patients with grade 1 or 2 disease that is presumed to be stage IA or IB have a greater than 
90% 5 year survival rate following TAH and BSO alone. Some authors advocate only 
palpating the relevant nodes and sampling enlarged nodes. (121, 143, 155, 159–162) 
However, inspection is not a sensitive method of detecting lymph node involvement as only 
10% of patients with nodal involvement will have grossly enlarged nodes. (156) It should be 
noted that women who do not undergo at least lymph node sampling is incompletely staged. 
(143) 
 
While lymph node sampling aims to obtain a representative biopsy, the goal of 
lymphadenectomy is to remove all lymph nodes in a specific anatomical distribution. (143) 
Multiple site lymph node sampling is associated with better survival rates than limited 
sampling, or no sampling at all. (143, 163) 
There may be para-aortic lymph node metastases, even in the absence of positive pelvic 
lymph nodes. (143, 164) There is some evidence to suggest that para-aortic lymph node 
dissection may confer a survival benefit in patients diagnosed with intermediate or high risk 
endometrial cancer. (143, 165) 
 
Given the importance of lymph node assessment in staging the tumour and planning 
treatment, complete pelvic lymph node dissection and extended lymph node dissection is a 
reasonable approach. (143) 
 
The role and method of sentinel node biopsy in detecting lymph node metastases is still 
unclear. (143, 166) A meta-analysis found that sentinel node biopsy has a 93% sensitivity in 
detecting nodal involvement in patients with endometrial carcinoma. (167)The site of 
injection is controversial; cervical, subserosal and hysteroscopically guided endometrial 
injection is possible. (143, 154, 166, 168–171) 
 
1.10.2 Adjuvant therapy 
 
Radiation therapy (RT) is the most common adjuvant modality for endometrial cancer. 
Traditionally chemotherapy was deemed ineffective. There has been a recent paradigm shift 
as four randomised control studies found that adjuvant whole pelvis external beam RT did 
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not improve disease specific or overall survival in stage I or stage II disease, despite 
improving local control. (172) 
The following patients should receive adjuvant treatment(173): 
 
 Low risk disease: Grade 1 or 2 endometrioid tumour that are confined to the 
endometrium requires no adjuvant treatment 
 Intermediate risk disease: Tumours that invade the myometrium (IA or IB) or occult 
cervical stromal invasion are candidates for adjuvant RT. Chemotherapy may be 
used for patients with high intermediate risk. 
 High risk: Patients with stage stage III disease (irrespective of histology), clear cell 
carcinoma and uterine serous carcinoma of any stage should receive chemotherapy 




1.11  Management options in endometrial cancer recurrence 
 
1.11.1   Local recurrence 
 
1.11.1.1  Surgery 
 
Retrospective reports demonstrate that surgical resection may enhance long-term 
recurrence free survival in selected patients who exhibit recurrence locally after primary 
surgery – as long as evidence of retroperitoneal involvement or extension of the disease to 
the pelvic side wall is not present.  Outcomes are most favourable in patients who present 
with an isolated vaginal recurrence and who are able to undergo complete resection. (174, 
175) Surgical resection is best reserved for the woman who has recurrent disease that can 
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1.11.1.2  Pelvic exenteration 
 
Isolated central pelvic recurrence after surgery and / or radiotherapy is rare, but does occur. 
Pelvic exenteration is associated with a high operative morbidity, but this procedure remains 
the only potentially curative option for those patients presenting with central recurrence after 
surgery and radiotherapy. (176) 
The best candidates are women who are medically fit for radical surgery and whose central 
vaginal recurrence is the only known site of the disease. 
 
 
1.11.1.3  Radiation therapy 
 
While attempted resection may represent an appropriate option for selected women with a 
localised vaginal recurrence, women with endometrial cancer are often overweight and 
present with co morbidities such as hypertension and diabetes mellitus.  These patients 
represent a particularly high-risk group for radical surgery.  Due to this, radiation therapy is 
commonly offered to women with an isolated vaginal or pelvic recurrence.  In this case 
surgery is reserved for radiation therapy failure.  Long-term survival rates in women who 
undergo radiation therapy after relapse range from 25 - 75%, with most reporting five-year 
survival rates of approximately 50% (Huh et al., 2007; Lin et al., 2005). 
 
 
1.11.2 Metastatic primary disease, pelvic side wall and distant 
recurrence 
 
1.11.2.1  Surgical cytoreduction 
 
If complete resection to no gross residual disease is possible, surgical cytoreduction may 
confer a survival benefit in women presenting with metastases or recurrent disease involving 
the pelvic side wall or distant sites. (9, 177) 
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1.11.2.2  Hormone therapy 
 
In patients with advanced endometrial carcinoma hormone therapy is a good treatment 
option, but it has certain limitations. Low grade tumours and those that express progesterone 
receptors (PR) are more likely to respond to hormone therapy than high grade tumours and 
those without hormone receptor expression. (2, 178, 179) Hormone therapy is 
recommended as initial therapy in patients with PR positive tumours. Chemotherapy is 
recommended for PR negative tumours. (180) 
 
When several progestins are combined (e.g. medroxyprogesterone acetate, megesteril 
acetate, etc.) response rates of as high as 56% have been reported, with low grade tumours 
having the best response to therapy. (178, 181) However, some studies demonstrated 
response rates as low as 15 – 20%. (182) 
 
Tamoxifen is a selective oestrogen receptor modulator (SERM). It is effective in women with 
advanced endometrial carcinoma with hormone receptor positive tumours. The response 
rate in these patients is 30 – 35%. (183) 
 
Tamoxifen and progestin is sometimes combined, the rationale being that progestins 
downregulate oestrogen receptor (ER) expression, limiting the effect of tamoxifen. 
Tamoxifen is associated with an increased risk of endometrial cancer when used in the 
chemoprevention and adjuvant treatment of breast cancer due to its oestrogen agonist 
effects. It also increases expression of cytosolic progesterone receptors. (184) 
 
A high percentage of endometrial carcinomas have GnRH receptors, but data on the efficacy 
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1.11.2.3  First line chemotherapy 
 
Single agent therapy 
First line monotherapy agents include doxorubicin, cisplatin, carboplantin, docetaxel, 
paclitaxel, topotecan and ixabepilone. Response rates vary from 12 – 28%. (187, 188) 
 
Combination chemotherapy 
Combination regimens have slightly better response rates (36 – 67%). (189) 
 
 
1.11.3  Treatment of advanced or recurrent endometrial cancer 
 
Women with metastatic or recurrent endometrial cancer represent a heterogeneous group. 
Depending on the previous treatment and the site of the recurrence, these patients may be 
managed with palliative or curative intent. Treatment options for recurrent disease include 
radiation therapy, surgery, hormone therapy and cytotoxic chemotherapy.   
 
Cure is not likely unless the localised recurrence is limited to the vaginal cuff.  This 
demonstrates the importance of close surveillance and monitoring after primary treatment 
with routine vaginal cytology and pelvic examinations. 
 
Endometrial cancer recurs in approximately 3 - 17% of women initially diagnosed with early 
stage endometrial cancer. (103, 190) Local recurrences predominate in women treated with 
surgery alone, while distant recurrences are more common in women treated with combined 
modalities. (191) 
Factors that predispose to the recurrence of endometrial cancer include: higher staged 
carcinomas, myometrial or cervical invasion, lymphatic spread, and histological subtype. 
(103) Papillary serous, clear cell and endometrioid carcinomas have the highest risk of 
recurrence. (103, 192) High-grade histological subtypes are also associated with have a 
higher risk of recurrence. (127) 






30 | P a g e  
 
1.12 Special clinical situations 
 
1.12.1 Synchronous ovarian and endometrial tumours 
 
Synchronous primary endometrial and ovarian tumours occur in 5% of patients with 
endometrial cancer and 10% of women with ovarian cancer. (143, 204, 205) Premenopausal 
women have a 5 – 29% higher risk of synchronous primary tumours. (143, 206) 
 
Synchronous primary tumours do not change the staging or operative treatment of 
endometrial cancer. (143) 
 
 
1.12.2 Inoperable patients 
 
Radiation therapy is an acceptable alternative in stage I patients who are medically unfit or 
unwilling to have surgery. These patients are staged according to the 1971 FIGO 
classification, and staging procedures include examination under anaesthesia, sounding of 
the uterus, endocervical curettage, hysteroscopy, cystoscopy, proctoscopy and imaging 
studies. (143) 
 
A retrospective review found that women older than 75 years who had either external beam 
radiation therapy and / or brachytherapy as they were poor surgical candidates, had disease 
specific survival rates of 93% and 73% at 1 and 3 years, respectively. Both groups had an 
overall survival rate of 28% at 2 years. (207) 
 
 
1.12.3 Fertility preservation 
 
Women of childbearing age with grade 1 or grade 2 endometrioid endometrial malignancy 
that is confined to the endometrium may be candidates for fertility preservation. Progestin 
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therapy is the mainstay of treatment in this group.(91, 208) Patients should be counselled 
extensively to allow them to make an informed decision. (208) 
A thorough evaluation prior to therapy (including dilation and curettage and imaging studies) 





1.13 Post treatment surveillance 
 
Post treatment surveillance consists mainly of monitoring the patient for symptoms and 
physical examination. 
 
The use of CA – 125 in posttreatment surveillance is controversial. (209) It may have a role 
in follow up if the initial levels were elevated. (143) Routine use of CA – 125 varies greatly 
across institutions. (209)It is recommended that CA – 125 only be monitored when clinically 
indicated. (209, 210) 
Vaginal cytology after initial treatment for endometrial cancer has a sensitivity of 40% in 
detecting vaginal recurrence and has poor detection rates compared to physical examination 
alone. (209, 211) 
The United States National Comprehensive Cancer Network  and Society for Gynecologic 
Oncology made the following recommendations (209): 
 
 Symptom review and clinical exam (including bimanual pelvic and speculum 
examination) every 3 – 6 months for two years, then every 6 – 12 months thereafter 
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1.14 Survival rates 
 
Appropriately treated endometrial adenocarcinoma have a survival rate of 80%. (190) More 
than 70% of women have FIGO stage I endometrial cancer, which carries a good prognosis. 
Stage III and IV disease carry a worse prognosis, but occurs only in 13% of cases. The 
mean survival time for stage III and IV endometrial carcinoma is 9 – 10 months. (212) Older 
age is associated with a poorer prognosis. (2) 
Table 5 shows the FIGO surgical stage and overall survival for endometrial cancer. This data 
is for patients treated between 1999 and 2001. The initial (1988) FIGO classification system 
is used. (23) 
 
Table 5: Endometrial carcinoma - FIGO surgical staging and overall 





Currently the management of endometrial carcinoma is individualised to the patient’s profile, 
fertility options and availability of surgical resources and expertise.  Currently there is no 
uniform screening protocol for endometrial cancer. This study aims to determine the 
predisposing factors, symptoms, treatment options and outcome in women with endometrial 
carcinoma in the South African context. This would enable us to make recommendations 
FIGO stage Overall survival (%) 
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regarding monitoring and implementing medical and surgical interventions with the least risk 




To determine the clinical profile and management of women treated for endometrial 
carcinoma in Durban, South Africa. 
 
 
1.17 Objectives of the study 
 
 To determine the clinical profile and risk factors of women presenting with 
endometrial carcinoma 
 To determine the frequency of the various stages of endometrial carcinoma 
 To determine the different management modalities 
 To determine the different subtypes of endometrial carcinoma 
 To determine the frequency and type of complications following treatment in women 
with endometrial carcinoma 
 To determine the number of women presenting with recurrent disease during the 
study period 
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CHAPTER 2:  
METHODOLOGY 
 
2.1. Study design and location of study 
 
This study was a retrospective chart review of all patients presenting to the Combined 
Gynaecology Oncology Clinic at Inkosi Albert Luthuli Central Hospital (IALCH) from the   
1January 2005 to 31 December 2010, with a histological diagnosis of endometrial 
carcinoma. 
 
2.2. Materials and methods 
 
The inclusion criteria were as follows: 
 
 All women presenting to the Combined Gynaecology / Oncology Clinic at IALCH 
between 1 January 2005 and 31 December 2010 with a histological diagnosis of 
endometrial carcinoma 
 
The exclusion criteria were: 
 
 Women with other types of carcinomas 
 
Eligible women were identified from a clinical database at IALCH, as all clinical information is 
captured on the Medicom database.  As IALCH functions as a tertiary referral centre all 
patients referred to IALCH with endometrial carcinoma are reviewed at the combined 
oncology clinic. Two hundred case files with a diagnosis of endometrial carcinoma were 
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The study variables studied included:  
 Race                                                                                                    
 Age  
 Age at menarche 
 Age at menopause 
 Obesity (BMI) 
 Parity 
 Polycystic ovarian syndrome (PCOS) 
 Hypertension 
 Diabetes mellitus 
 Familial predisposition 
 History of breast cancer 
 History of combined oral contraceptive use 
 Postmenopausal bleeding 
 FIGO staging of the endometrial carcinoma 
 Histological subtype of endometrial carcinoma 
 Radiation therapy to the pelvis 
 HIV status 
 Management and postoperative complications 
 
Pathological staging in this study was designated according to the 1988 FIGO Classification 
of Endometrial Cancer. In 2009 FIGO introduced revised staging criteria for endometrial 
cancer. In the unit where the data was collected from 2005 – 2010, the 1988 FIGO 
classification was used. 
 
Confidentiality of all subjects was maintained by allocating a study number and no names 
were recorded on the data sheet (Annexure 1). 
 
Pap smear results were grouped into normal or abnormal. Abnormal Pap smear included 
those women who had low-grade squamous intraepithelial lesion (LGSIL), high-grade 
squamous intraepithelial lesion (HGSIL) or Human papilloma virus (HPV). 
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On the basis of body mass index (BMI) (calculated as weight [kg]/height [m]2), patients were 
classified into five groups: Underweight (BMI < 20), normal weight (BMI: 20 - 24.9), 
overweight (BMI 25 - 29.9), obese (BMI 30 - 35) and morbidly obese (BMI ≥ 35).  
Length of hospital stay was defined as duration of hospitalisation from admission to 
discharge.  
 
2.3. Statistical analysis 
 
Data was electronically captured using MS Excel and imported into SPSS version 22 (SPSS 
Inc, Chicago) for analysis.  Descriptive analysis was performed. Categorical variables were 
presented as frequency counts and percentages while quantitative variables were 
summarised using mean, standard deviation and range. A p - value < 0.05 was considered 
to be statistically significant.  A p - value was obtained using the analysis of variance 
(ANOVA) test for the study variables (age, surgery time, hospital stay) in the different BMI 
groups.  
 
2.4. Ethical considerations 
 
The study was approved by the Biomedical Research Ethics Committee (BREC), 
Postgraduate Committees of the University of KwaZulu Natal, the hospital management of 
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During the 6 year study period extending from 1 January 2005 to 31 December 2010,16 279 
malignancies were identified at first visit to Inkosi Albert Luthuli Central Hospital (IALCH).  Of 
the 16 279 malignancies from the oncology database, there were 3 002 gynaecological 
malignancies, giving a proportion of 18.4% (3 002 / 16 279).  
 
After analysis of patient records, 200 (6.7%) of the 3 002 gynaecological malignancies were 
diagnosed with endometrial carcinoma. The yearly distribution of endometrial carcinomas is 
shown in Table 6. 
 
Table 6: Yearly distribution of endometrial carcinoma at IALCH 
Year No. of endometrial carcinomas / No. of 







31 / 200 (15.5) 
29 / 200 (14.5) 
31 / 200 (15.5) 
38 / 200 (19.0) 
35 / 200 (17.5) 
36 / 200 (18.0) 
 
 
3.2. Demographics and clinical characteristics 
 
The mean ± SD age of the 200 patients was 63.8 ± 9.4 (range: 23 – 83) years.  The median 
age was 64.5 years.  Thirteen (6.5%) patients were below the age of 50 years and 187 
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(93.5%) of the patients were above 50 years of age.  The median parity was 4. The majority 
(n = 123; 61.5%) of patients were in the 1 - 4 parity group. 
 
The study population consisted of four racial groups.  Ninety five (47.5%) were Indian, 92 
(46%) were Black, 12 (6%) were White, and 1 (0.5%) was Coloured. There was no 
difference in the age (years) between Indian and Black patients, who made the greater part 
of our study population (63.2 ± 9.7 vs. 64.5 ± 9.3; p = 0.3), but there was a significant 
difference in the BMI between the two racial groups (29.6 ± 3.9 vs. 32.2 ± 7.6; p < 0.004).  
 
 
Table 7: Comparison of demographic details in black and Indian 
populations 
Variable Black 
(n = 92; 
46%) 
Indian 
(n = 95; 
47.5%) 
White 
(n = 12; 6%) 
Coloured 
(n = 1; 0.5%) 
p-value 
 
Age 64.5 ± 9.3 63.2 ± 9.7 63.4 ± 6.2 62 0.03 
BMI 32.2 ± 7.6 29.6 ± 3.9 29.8 ± 4.2 32 0.04 
 
 
HIV status was documented as positive in 13 (6.5%) cases and negative in 187 (93.5%) 
cases. All 200 patients had validated HIV test results.  
 
Thirteen (6.5%) patients presented with abnormal uterine bleeding in the premenopausal 
period. One hundred and eighty seven (93.5%) patients presented with postmenopausal 
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Table 8: Demographic details of women with endometrial carcinoma 
(n = 200) 
Age (years) Mean ± SD (range) 
 
63.8 ± 9.4 (23 – 83) 
Parity Median (range) 
 
4 (0 – 11) 
Parity groups (%) 
Nulliparous 
Low parity (1 – 2) 
Multiparous (3 – 4) 

























Presenting symptoms at diagnosis (%) 






Haemoglobin in g/dl 




10.88 ± 1.2 (6.8 – 14) 
10.6 
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3.3. Histopathological results at diagnosis 
 
Table 9 lists the histopathological results.   
 
Table 9: Histopathological results (n = 200) 















3.4. Histopathological results in different race groups 
 
Ninety two (46%) black patients and 95 (47.5%) Indian patients were diagnosed with 
endometrial carcinoma.  There was a significant difference between the groups with respect 
to the endometrioid type (86.3% vs. 58.7%; p < 0.001) and carcinosarcoma, serous and 
clear cell subtypes (13 vs. 38; p < 0.001). Histopathological results in the different racial 
groups are listed in Table 10. 
 
 


























3   (3.3) 
82 (86.3) 
 
7   (7.4) 
 
5   (5.3) 
 
1   (1.0) 
11 (91.7) 
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3.5. Predisposing factors affecting endometrial carcinoma 
 
3.5.1. Endometrial carcinomas by age 
One hundred and eighty seven (93.5%) endometrial carcinomas occurred in patients over  
50 years of age. Thirteen (6.5%) endometrial carcinomas occurred in patients under 50 
years of age. Endometrial carcinomas stratified into different age groups are shown in Table 
11.  
Table 11: Number of endometrial carcinomas by age 
Age (years) Number % 
20 – 29 
30 – 39 
40 – 49 
50 – 59 
60 – 69 

















3.5.2. Endometrial carcinomas by body mass index 
Endometrial carcinomas by body mass index are graphically depicted in Figure 1.  There 
was 1 (0.5%) patient who was classified as underweight with a BMI < 20, 13 (6.5%) patients 
were classified as normal weight (BMI 20 – 24.9),  89 (44.5%) patients were classified as 
overweight (BMI 25 – 29.9), 68 (34%) patients were classified as obese (BMI 30 – 35) and 
29 (14.5%) patients were classified as morbidly obese with a BMI ≥ 35.   










    BMI 
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3.5.3. Other predisposing factors for endometrial carcinoma 
 
Other predisposing factors affecting endometrial carcinoma are shown in Table 12. 
 
Table 12: Predisposing factors affecting endometrial carcinoma 
Factor Data 
Menarche (years)    
Mean ± SD 
Median  
 
14.4 ± 1.2 (range: 9 19) 
14 
Categorisation of menarche (years)(%) (n=128) 
≤ 12 






Menopause (%)     
Yes 





51.05 ± 2.6 (range: 37 – 60) 
51 
13 (6.5) 













Patients receiving tamoxifen 
 
4 (2) 
Comorbidities (%)   
Hypertension 
Diabetes 
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Endometrial thickness (mm)    
Mean ± SD 
Median 
 
22.1 ± 5.9 (range: 5 – 44) 
22 
Hormone replacement therapy (%)   
Yes 
Type of HRT 
       -  Oestrogen 








Combined oral contraceptive (years) (%)    
Yes 












3.6. Methods of diagnosing endometrial carcinoma 
 
Table 13: Methods of diagnosing endometrial carcinoma 
Postoperative modality Number Percentage 








3.7. Cervical Papanicolaou Smear results 
 
Abnormal Pap smear results were observed in 88 (44%) patients. Pap smear results are 
shown in Table 14. 
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Table 14: Cervical Papanicolaou smear results 















Table 15: Relationship between abnormal cervical cytology and type 
of endometrial carcinoma 
Type of endometrial 




Endometrioid (n = 147) 
 
Carcinosarcoma (n = 32) 
 
Serous (n = 17) 
 

















3.8. Treatment of endometrial adenocarcinoma 
 
Twenty nine (14.5%) patients were managed medically and 171 (85.5%) were managed 
surgically.  
 
3.8.1. Non-surgical therapy  
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Table 16: Primary mode of non-surgical therapy (n=29) 
Primary mode of non-surgical treatment Yes (n)(%) No (n)(%) p-value 













3   (10.3) 
 



















3.8.2. Surgical therapy 
 
One hundred and seventy one (85.5%) patients had surgical intervention. The peri operative 
parameters of these women are shown in Table 17. One hundred and fifty (87.7%) of these 
women were treated with adjuvant radiotherapy and / or chemotherapy, according to 
pathological findings at time of surgery. In 21 (12.3 %) patients surgical therapy was the only 
mode of therapy. 
 
Type of surgery 
 
 Total abdominal hysterectomy and bilateral salpingo-oopherectomy (n = 161) 
 Vaginal hysterectomy (n = 5) 
 Laparascopic assisted vaginal hysterectomy (n = 5) 
  
Duration of surgery  
 
The mean ± SD (range) duration of surgery was 83.9 ± 12.9 (60 – 120) minutes. The median 




The mean ± SD (range) number of days of hospital stay was 7.7 ± 0.9 (4 - 11) days. The 
median number of days confinement at hospital was 8 days. 
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Adjuvant therapy following surgery 
 
The adjuvant therapy received by patients is as follows (n = 150): 
 
 External-beam radiotherapy + chemotherapy (n = 57) 
 Vaginal brachytherapy + chemotherapy (n = 6) 
 External-beam radiotherapy  (n = 56) 
 Vaginal brachytherapy (n = 31) 
 
 
Table 17: Peri operative parameters of women having primary 
surgical treatment (n=171) 
 Number (%) 
Procedure 
TAH + BSO 
Vaginal hysterectomy 




5     (2.9) 
5     (2.9) 
Duration of surgery (min) 





83 ± 12.9 
60 – 120 
80 
Hospital stay (days) 





7.7 ± 0.9 
4 – 11  
8 
Postoperative complications (%) 
Wound sepsis 
Deep vein thrombosis 
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3.9. Perioperative variables based on body mass index   
 
Table 18: Perioperative variables based on body mass index 
BMI Normal  Overweight Obese Morbidly 
obese 
p -  value 
Number of patients 
BMI* 
Age (years)* 
Surgery time (min)* 
Hospital stay (days)* 
13 
23.2 ± 1.6 
60.3± 13.3 
82.5 ± 12.7 
7.9 ± 1.1 
89 
27.9 ± 1.4 
63.4 ± 9.0 
81.3 ± 11.5 
7.7 ± 1.0 
68 
34.8 ± 6.0 
64.7 ± 9.0 
86.6 ± 13.5 
7.7 ± 0.9 
29 
41.6 ± 7.6 
63.45 ± 8.4 
92.3 ± 16.7 






* Expressed as mean ± SD 
 
3.10. Complications following surgical procedures 
 
Twenty (11.7%) of the 171 patients who had undergone surgery developed complications. 
Eight (4.7%) patients developed wound haematomas, 5 (2.9%) had wound sepsis, 4 (2.3%) 
developed deep vein thrombosis and 3 (1.8%) had urinary tract infection. Complications are 
listed in Table 19. 
Eighteen (11.2%) complications occurred in patients who had total abdominal hysterectomy 
and bilateral salpingo-oophorectomy, 1 (20%) in a patient who had a vaginal hysterectomy 
and   1 (20%) in a patient who had a laparoscopically assisted vaginal hysterectomy.  
 
Table 19: Complications following different surgical procedures 
Surgical procedure TAH + BSO 
n=161 (%) 
VH            
n=5 (%) 
LAVH         
n=5 (%) 
Wound sepsis 
Deep vein thrombosis 














Total 18 (90) 1 (5) 1 (5) 
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Perioperative complications were not associated with age (p = 0.36), race (p = 0.39) and 
cancer stage (p = 0.45).  Perioperative complications were associated with a prolonged 
hospital stay (p = 0.02).  
 
3.11. Relationship between complications and BMI 
 
The number of perioperative complications occurring with an increased BMI, are shown in 
Table 20.  There was a significant association between BMI (obese 31% vs. normal 3%) and 
perioperative complications (p < 0.001). 
 
 
Table 20:  Number of complications based on BMI (n=109) 
Variable BMI Number of complications % 
Normal (n = 13) 
Overweight (n = 89) 
Obese (n = 68) 
Morbidly obese (n = 29) 
20 – 24.9 
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Table 21: Post-surgical management of women with endometrial 
carcinoma (n = 200) 
Postoperative modality Number (%) 





















23   (11.5) 
1     (0.5) 












77   (38.5) 
117 (58.5) 
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3.13. Staging of endometrial adenocarcinoma 
As only 5 of the 200 patients underwent pelvic or para-aortic lymphadenectomy, the staging of 
endometrial carcinoma is incomplete. 
 
Table 22A: Incompletely staged endometrial carcinoma 
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The frequency of the various stages of endometrial carcinoma is depicted in Table 22B. 
 
Table 22B: Distribution of histological subtypes by stage 
 Histology result 
Staging Endometrioid 
 




n = 32 (16%) 
Serous 
 
n = 17(13.5%) 
Clear cell 
 
n = 4 (2%) 
Total 
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3.14. Recurrence details 
 
3.14.1. Demographic profile of endometrial carcinoma recurrence 
 
Table 23: Demographic profile of endometrial recurrence 





Age (years) at recurrence 




63.96 ± 8.5 
47 – 81  
64 






9   (32.14) 
7   (25.0) 
Time elapsed following initial treatment (months) 




21 ± 25.2 





3.14.2 Histology type and recurrence of endometrial carcinoma following 
treatment 
 
The number of recurrences according to histology type is shown in Table 24. 
 
Table 24: Histological type at diagnosis and recurrence of 
endometrial carcinomas following treatment 
 
Histology type Recurrence (n = 28) Percentage 
Endometrioid (n = 147) 
Carcinosarcoma(n = 32) 
Serous (n = 17) 
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3.14.3. Initial treatment of endometrial carcinomas that recurred 
 
Table 25: Initial treatment of endometrial carcinomas that recurred 
 
Treatment Recurrence (%) 
Adjuvant therapy following surgery (n=150) 
 
     External beam radiotherapy & chemotherapy 
     Vaginal brachytherapy & chemotherapy 
     External beam radiotherapy 





 2 (1.3) 
7 (4.7) 
3 (2) 
Non-surgical (medical) (n=29) 
 
     External beam radiotherapy & chemotherapy 
1 
 
   1 
 
3.14.4. Cytology, histology and staging results of patients with 
endometrial carcinoma recurrence 
 
Results of patients with recurrence of endometrial carcinoma is shown in Table 26. 
 
Papanicolauo result of patients with recurrence of endometrial carcinoma 
 





The Pipelle results, of the 28 patients who had recurrence, showed that 25 (89.3%) patients 
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Table 26: Cytology, histology and staging results of patients with 
endometrial carcinoma recurrence 





Low grade squamous intraepithelial lesion 
High grade squamous intraepithelial lesion 
Human papilloma virus 
 
Pipelle result 
     Non-representative  
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In our study, the proportion of endometrial carcinoma to the total number of gynaecological 
malignancies was 6.7% over the 6-year study period. 
 
The age of diagnosis of endometrial carcinoma peaks in the seventh decade of life. In our 
audit, the median age at presentation of endometrial carcinoma was 64.5 years, compared 
to 60 years of age in the USA. (11)The worldwide median age at diagnosis is 63 years.(67) 
Thirteen (6.5%) patients were premenopausal and187 (93.5%) were postmenopausal. 
Previous studies have suggested that up to 14% of women with endometrial carcinoma are 
premenopausal. (213) It has been reported that women younger than 40 years of age make 
up 5% of endometrial carcinoma cases, and 10 – 15% of cases occur in women less than 
50 years of age.(180)  Thirteen (6.5%) of our patients were below the age of 50 years and 4 
(2%) were below 40 years of age. This is consistent with international studies which have 
shown that 5 - 30% of the endometrial cancer population is found to be 
premenopausal.(214) 
 
In our study the majority of the endometrial carcinomas occurred in the 60 - 69 age group, 
compared to the 50 - 54 age group in a study done in 1996 by McPherson et al. (78) In a 
more recent study, Ali reported two peaks (age 55 - 59 years, and 65 - 69 years) at which 
endometrial carcinoma occurred.(215) 
 
All the patients in this study population presented with postmenopausal bleeding.  This is 
likely due to late presentation of patients in the background of a resource limited setting. 
Seven (3.5%) endometrial carcinomas were diagnosed by dilatation and curettage compared 
to193 (96.5%) diagnosed by Pipelle endometrial biopsy.    
The sensitivity of endometrial biopsy for the detection of endometrial abnormalities is 
reportedly  as high as 96%.(17) 
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Increased age and obesity were important predisposing factors for endometrial carcinoma 
that were identified in this study.  In the USA, age, obesity and unrestricted use of oestrogen 
therapy were listed as being important risk factors for the development of endometrial 
carcinoma.(67)  In this study the risk of endometrial carcinoma was about seven times 
higher in overweight patients, and five times higher in obese women compared to patients 
with normal weight.  In a recent study, it has been reported that endometrial carcinoma risk 
is 32% higher in overweight women and 2.5 times higher in obese women compared to 
women with a healthy weight.(216) In this study 75 (66.4%) patients were exposed to 
unopposed oestrogen despite the associated increased risk for endometrial carcinoma. This 
is an alarming statistic as these patients should ideally have received add-back progestin 
therapy.  
 
Obesity was significantly associated with operating time. One of the reasons postulated is 
that in obese patients there is greater difficulty in operative access.  There were more 
perioperative complications in women with increased BMI (obese 31% vs. normal 3%), 
which was found to be statistically significant. 
 
Immune deficiency has been implicated in endometrial carcinoma. (127)In our study, 13 
(6.5%) women with endometrial carcinoma were infected with HIV. None of the women who 
were HIV positive in our study had recurrence during the study period.  In addition to the 
AIDS-defining cancers such as non-Hodgkin’s lymphoma, Kaposi’s sarcoma, and cervical 
cancer, higher rates of Hodgkin’s disease and anal cancer have been consistently reported 
to be associated with HIV / AIDS patients. (217–219) HIV status as a risk factor for 
endometrial carcinoma needs to be addressed further in a larger study. 
 
Patients who have breast carcinoma are often treated with tamoxifen to reduce the risk of 
recurrence. In our study, 4 (28.6%) of the 14 patients with breast cancer were treated with 
tamoxifen. Tamoxifen acts as an anti-oestrogen in breast tissue, but it has an oestrogenic 
effect in the uterus and can cause endometrial hyperplasia, which has the potential for 
malignant change.(220) Despite the increased risk of endometrial cancer in tamoxifen users, 
international guidelines do not recommend routine endometrial surveillance in asymptomatic 
patients. (87, 94) 
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Eighty eight (44%) patients with endometrial carcinoma had abnormal Pap smears, with no 
evidence of abnormal endometrial cells.  Patients presenting with HSIL or persistent LSIL 
were referred for colposcopy and LLETZ biopsy. Patients with postmenopausal bleeding and 
abnormal cervical cytology warrant careful clinical examination and investigations to exclude 
cervical cancer, which is more common in the South African setting. A negative Pap smear 
does not rule out the presence of endometrial cancer and it should not be used as a 
diagnostic test for endometrial carcinoma. Bakkum-Gamez et al. suggest that menopausal or 
perimenopausal patients with atypical / neoplastic endometrial cells on the Pap smear 
should be further investigated for endometrial neoplasia. (117) Münstedt et al. reported that 
a positive Pap smear result might have prognostic significance.(120) In a more recent study 
by Jones et al. one hundred and forty nine women demonstrating cytologically benign 
endometrial cells on Pap smear were followed up within a 12 month period.  The results 
showed that 60.84% had no endometrial pathology, 35.66% presented with benign 
pathologic changes and 3.50% demonstrated endometrial carcinoma.(221) 
 
Advancing age was identified as an important risk factors for endometrial carcinoma. In our 
study 187 (93.5%) endometrial carcinoma cases occurred in women older than 50 years of 
age, with a median age of 64.5 years. Four (2%) patients were under the age of 40 years. 
Endometrial carcinoma can occur at any reproductive age. (213) Early menarche, defined as 
menarche occurring prior to  12 years of age, is associated with endometrial cancer.(222) 
The results of a pooled analysis demonstrated that endometrial carcinoma risk among 
parous women is 11% higher in those aged < 13 years at menarche compared with those 
aged > 13 years at menarche. (223) Menarche in 4 of our patients occurred at < 12 years of 
age. Ali reported that early menarche, which ranged between 11-14 years, occurred in 
45.3% of their endometrial carcinoma patients. (215) 
 
Fifty five (27.5%) patients had a history of combined oral contraceptive use. The mean 
duration of combined oral contraceptive use was 6.15 (range: 3 – 10) years. In a case 
controlled study, Urban et al. compared women who had never used hormonal 
contraceptives to women who used oral and / or injectable contraceptives for a total of 5 
years or longer. The women in the latter group had a significantly lower risk of endometrial 
cancer, whilst women who used these contraceptives for less than 5 years had no significant 
difference in risk.(224) 
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A number of epidemiological studies reported diabetes(225, 226) and hypertension(43, 227) 
to be a risk factor for developing endometrial cancer. One hundred and eight (54%) patients 
in the audit were hypertensive, 8 (4%) were diabetic and 52 (26%) were both hypertensive 
and diabetic. Hypertension and diabetes mellitus are both influenced by lifestyle and 
associated with an increased BMI. 
 
The measurement of endometrial thickness by TVUS is used to determine the risk of 
endometrial carcinoma in women presenting with postmenopausal bleeding. There are 
conflicting reports on the endometrial thickness measurement for the exclusion of 
endometrial malignancy. In our study, the median endometrial thickness was 22 (range: 5 – 
44) mm. Only two patients had an endometrial thickness of ≤ 5mm.  A review of the clinical 
profile of these two patients reveals that they were both in the eight decade of life, with one 
having a Pap smear result showing LSIL and the other with HPV.  Saha et al. found that 
there was an 8% chance of missing a thickened endometrium when transvaginal ultrasound 
is used to measure the endometrial thickness and these authors recommended that 
transvaginal ultrasound measurement should be interpreted with caution, and patients with 
persistent postmenopausal bleeding and a thin endometrium on transvaginal ultrasound 
should undergo a hysteroscopic examination.(126) 
 
In our study, only 6 (3%) patients had an endometrial thickness of ≥ 10mm.  Trans vaginal 
ultrasound was performed in only ten patients. A number of studies showed that endometrial 
thickness of ≤ 5mm is associated with a low risk for endometrial carcinoma.(228, 229) Smith-
Bindman et al. reported that if the thickness of the endometrium is > 5mm, the risk of 
endometrial carcinoma is approximately 7.3% and < 0.07% if the endometrium is   ≤ 5mm in 
postmenopausal women. (136) 
 
In our retrospective study of two hundred patients treated for endometrial carcinoma, type I 
comprised 143 (71.5%) patients while 57 (28.5%) patients had type II endometrial 
carcinoma. Treatment consisted of surgical, non-surgical and adjuvant treatment following 
surgery. The overall recurrence rate was 14%.  
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In this study 95 (47.5%) endometrial carcinomas were diagnosed in Indian women, and 92 
(46%) in black women. This must be interpreted in a context where the black population 
make up 86% of the population in Kwa Zulu Natal, and the Indian population make up only 
7.4%.(230) 
 
There was a significant difference in types of endometrial cancer between the groups. Eighty 
two (86.3%) Indian patients diagnosed with endometrial carcinoma presented with an 
endometrioid subtype, whereas only 54 (58.7%) black women had the endometrioid subtype. 
Twenty three (25%) black patients diagnosed with endometrial carcinoma presented with 
carcinosarcoma, whereas only 7 (7.4%) Indian women presented with this subtype.  In the 
United States, white women are more likely to be diagnosed with endometrial cancer than 
African-American, Asian, or Hispanic women. (43) 
 
Twenty (11.7%) of the 171 patients experienced perioperative complications. All the 
complications reported were short term. In another retrospective study of 233 women with 
endometrial carcinoma, 24 (10.3%) patients experienced complications. (231) 
 
The treatment of choice for endometrial carcinoma is surgery. It is estimated that over 90% 
of women with endometrial cancer receive primary surgical management. (192)In our study 
29 (14.5%) patients were managed non-surgically.  This included 3 patients who were 
medically unfit for surgery. The non-surgical treatment included vaginal brachytherapy or 
external beam radiotherapy and / or chemotherapy.  One hundred and seventy one (85.5%) 
patients were treated surgically; and 150 of these patients received adjuvant radiotherapy 
and / or chemotherapy. 
 
 
The treatment protocol at IALCH for endometrial cancer is based on surgical staging. 
 Stage IA (low risk): TAH + BSO 
 Stage IA (high risk), II: TAH + BSO + lymphadenectomy (pelvic and para-aortic) 
 Stage III: Radiotherapy 
 Stage IV: Chemotherapy or progestogen therapy 
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There were 2 deaths, both being diagnosed with endometrioid adenocarcinoma. Both of 
these patients received primary surgical treatment and adjuvant radiotherapy, and were 
staged as stage IIIa. One patient demised 2 years and one month after primary treatment, 
and the other 6 months after primary treatment. 
 
The recurrence rate of 14% observed in our study is within the range of 3 - 17% reported in 
the literature.(190, 210) The sites of recurrence listed in the literature are vaginal, pelvic, and 
distant metastases.  The commonest site of recurrence is in the vagina.  (179, 232) The 
vaginal vault, pelvis and distant metastases were the commonest sites of recurrence in our 
patients, with the vagina being the most common.  
 
The time to recurrence of endometrial carcinoma ranged from as early as 2 months to 120 
months with a median of 12 months.  Recurrence occurred at the vaginal vault alone in 12 
(42.8%) patients. In an earlier study by Foote and Proietto, one hundred and nineteen 
patients treated for FIGO stage I endometrial carcinoma were reviewed retrospectively to 
determine if adjuvant radiotherapy reduced disease recurrence. The overall recurrence rate 
was 10.1%. Recurrence at the vaginal vault alone occurred in 3.4%of patients. (233) 
 
Studies have reported time to recurrence of 24 – 36 months.(191) It has also been reported 
that papillary serous carcinoma, clear cell carcinoma and high-grade histological subtypes 
have the highest risk of recurrence. (61, 127) Twenty two (15%) of the 28 cases of 
recurrence in our study, occurred in patients diagnosed with type I endometrioid 
adenocarcinoma. Only 6 (11.3%) cases recurred in patients with type II endometrial 
carcinoma. Our type II carcinoma numbers were too small to make any comparison with 
other studies. 
 
One hundred and sixteen (58%) of our patients were diagnosed with stage I disease. Thirty 
six (18%) patients had stage II disease, 37 (18.5%) had stage III disease and 11 (5.5%) 
patients had stage 4 disease. The National Cancer Institute reported that in the period 2006 
– 2012, 67% of patients diagnosed with endometrial cancer had localised disease confined 
to the primary site, 21% had regional lymph node spread and 8% had distant metastases. 
Four percent were not staged.(234) 
 




The first limitation was that the study was retrospective in nature.  As surgical procedures 
were performed by surgeons with different level of experience some study parameters, such 
as operative time and perioperative complications, may be influenced by the skill of the 
surgeon. 
 
Comprehensive data on certain study parameters were not available. This includes, inter 
alia, whether or not all patients completed planned adjuvant treatment. Data obtained was 
limited by the amount of data recorded in patient charts.  
 
Only 5 patients had pelvic and/or para aortic lymph node biopsies performed. Pelvic and 
para aortic lymphadenectomy was not performed in the unit between 2005 and 2010. This 
may have resulted in under staging of certain patients with endometrial carcinoma. 
 
Transvaginal ultrasound was only performed in 10 (5%) of patients. This is an important 
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CHAPTER 5:  




Even though endometrial carcinoma is primarily diagnosed after menopause, it may also 
occur in young women of any age. This descriptive study showed that 93.5% of patients 
presenting with endometrial carcinoma were over 50 years of age. The most frequently 
diagnosed histological subtype was endometrioid adenocarcinoma (73.5%). Approximately 
45.5% of patients were diagnosed in the seventh decade of life. The majority of patients 
presenting with endometrial carcinoma were overweight (44.5%).  
 
Approximately 76% of patients presented with stage I or stage II disease. Surgical 
intervention was the treatment of choice with 171 (85.5%) patients undergoing surgical 
intervention, and 150 of these patients receiving adjuvant therapy. Advancing age and 
obesity were the two most important predisposing factors for endometrial carcinoma. 
 
5.2. Recommendations 
1. Risk factors that are modifiable include obesity, sedentary lifestyles and use of 
unrestricted oestrogen. 
2. The complications reported are short term complications observed during 
hospitalisation. It would be valuable to analyse long term complications of the same 
study population. 
3. Any patient irrespective of age with persistent vaginal bleeding should be 











1. Gerli S, Spanò F, Di Renzo GC. Endometrial carcinoma in women 40 year old or younger: a case 
report and literature review. Eur Rev Med Pharmacol Sci 2014; 18(14):1973–8. 
2. Galaal K, Al Moundhri M, Bryant A, Lopes AD, Lawrie TA. Adjuvant chemotherapy for advanced 
endometrial cancer. Cochrane Database of Systematic Reviews 2014; (5). 
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: A Cancer 
Journal for Clinicians 2011; 61(2):69–90. 
4. Lucas WE. The Epidemiology of Endometrial Cancer. GLOWM 2009. 
5. Holman L, Lu k. The epidemiology of endometrial cancer. GLOWM 2012. Available from: URL: 
https://www.glowm.com/section_view/heading/The%20Epidemiology%20of%20Endometrial%20Ca
ncer/item/236#ref. 
6. Wilde LA de, Steinberg WJ, Nel M. Sonar findings of the uterus in patients on 
medroxyprogesterone acetate (Depo Provera) 150 mg injection. South African Family Practice 2014; 
51(6):486–8. 
7. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011. CA: A Cancer Journal for Clinicians 
2011; 61(4):212–36. 
8. Kim SM, Shin SJ, Bae JG, Kwon KY, Rhee JH. Endometrial adenocarcinoma in a 13-year-old girl. 
Obstetrics & Gynecology Science 2015; 59(2):152–6. 
9. Hoffman BL, Williams JW. Williams gynecology. 2nd ed. New York, London: McGraw-Hill Medical; 
2012. 
10. Herbst M. Fact sheet on the top ten cancers per population group: Cancer Association of South 
Africa (CANSA); 2015. Available from: URL: http://www.cansa.org.za/files/2015/09/Fact-Sheet-Top-
Ten-Cancers-per-Population-Group-Sept-2015.pdf. 
11. Burke WM, Orr J, Leitao M, Salom E, Gehrig P, Olawaiye AB et al. Endometrial cancer: a review 
and current management strategies: part I. Gynecol Oncol 2014; 134(2):385–92. 
12. National Institute for Occupational Health. Cancer in South Africa 2011 full report: National 
cancer registry: National Institute for Occupational Health; 2011. Available from: URL: 
http://www.nioh.ac.za/assets/files/NCR_2011%20cancer%20tables%20(2)(1).pdf. 
13. Rose P. Endometrial Carcinoma. New England Journal of Medicine 1996; 335(9):640–9. 
14. Duncan KA, Drinkwater KJ, Frost C, Remedios D, Barter S. Staging cancer of the uterus: a national 
audit of MRI accuracy. Clin Radiol 2012; 67(6):523–30. 
15. Herbst M. Fact sheet on cancer of the uterus: Cancer Association of South Africa (CANSA); 2016 
[cited September 2016]. Available from: URL: http://www.cansa.org.za/files/2016/08/Fact-Sheet-
Cancer-of-Uterus-NCR-2011-web-August-2016.pdf. 
16. Chen L-m, Berek JS. Patient Education: Endometrial cancer diagnosis and staging: Beyond the 
basics: UpToDate. Available from: URL: 
http://www.plagscan.com/highlight?doc=10034460&source=58&cite=11#jump. 
64 | P a g e  
 
17. Wahda MT, Manal TA, Safwan I. Histopathological interpretation of abnormal uterine bleeding 
after the age of 40 years. The Iraqi Postgraduate Medical Journal 2010:274–82. 
18. Mohammed AAA, Mohammed HA, Ismail O. Khalid, Mahgoub M. Kier, Niemat M. Adam. 
Histopathological pattern of endometrial sampling in abnormal uterine bleeding. European 
Academic Research 2015; 3(4):3877–86. Available from: URL: 
http://euacademic.org/UploadArticle/1776.pdf. 
19. Bryan S. Abnormal vaginal bleeding. Emerg Med (Fremantle) 2003; 15(3):215–8. 
20. Oehler MK, Rees MCP. Menorrhagia: an update. Acta Obstet Gynecol Scand 2003; 82(5):405–22. 
21. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J 
Gynaecol Obstet 2009; 105(2):103–4. 
22. Benedet JL, Bender H, Jones H3, Ngan HY, Pecorelli S. FIGO staging classifications and clinical 
practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic 
Oncology. Int J Gynaecol Obstet 2000; 70(2):209–62. 
23. Plaxe SC, Mundt AJ. Overview of endometrial carcinoma: UpToDate. Available from: URL: 
https://www.uptodate.com/contents/overview-of-endometrial-
carcinoma?source=search_result&search=Endometrial%20cancer&selectedTitle=2~150. 
24. Haltia U-M, Butzow R, Leminen A, Loukovaara M. FIGO 1988 versus 2009 staging for endometrial 
carcinoma: a comparative study on prediction of survival and stage distribution according to 
histologic subtype. J Gynecol Oncol 2014; 25(1):30–5. 
25. Owings RA, Quick CM. Endometrial intraepithelial neoplasia. Arch Pathol Lab Med 2014; 
138(4):484–91. 
26. Emons G, Beckmann MW, Schmidt D, Mallmann P. New WHO classification of endometrial 
hyperplasias. Geburtshilfe Frauenheilkd 2015; 75(2):135–6. 
27. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study 
of "untreated" hyperplasia in 170 patients. Cancer 1985; 56(2):403–12. 
28. Chiang JW. Uterine cancer: Medscape; 2016. Available from: URL: 
http://emedicine.medscape.com/article/258148-overview. 
29. Luo L, Luo B, Zheng Y, Zhang H, Li J, Sidell N. Levonorgestrel-releasing intrauterine system for 
atypical endometrial hyperplasia. Cochrane Database Syst Rev 2013; (6):CD009458. 
30. Giuntoli R, Zacur H. Classification and diagnosis of endometrial hyperplasia: UpToDate; 2014. 




31. Baak JP, Orbo A, van Diest PJ, Jiwa M, Bruin P de, Broeckaert M et al. Prospective multicenter 
evaluation of the morphometric D-score for prediction of the outcome of endometrial hyperplasias. 
Am J Surg Pathol 2001; 25(7):930–5. 
32. Mutter GL, Baak JPA, Crum CP, Richart RM, Ferenczy A, Faquin WC. Endometrial precancer 
diagnosis by histopathology, clonal analysis, and computerized morphometry. J. Pathol. 2000; 
190(4):462–9. 
65 | P a g e  
 
33. National cancer institute. Endometrial cancer treatment: Health professional version: National 
cancer institute; 2017. Available from: URL: https://www.cancer.gov/types/uterine/hp/endometrial-
treatment-pdq. 
34. Levison DA, Muir R. Muir's textbook of pathology. 14th ed. London: Hodder Arnold; 2008. 
35. Zhang Y, Wang J. Controversies in the management of endometrial carcinoma. Obstet Gynecol 
Int 2010; 2010:862908. 
36. Montejo M, Werner TL, Gaffney D. Current challenges in clinical management of endometrial 
cancer. Adv Drug Deliv Rev 2009; 61(10):883–9. 
37. Ronnett BM, Zaino RJ, Ellenson LH, Kurman R. Blaustein’s pathology of the female genital tract: 
Endometrial carcinoma. 5th ed. New York: Springer-Verlag; 2002. 
38. Barakat RR, Markman M, Randall M. Principles and practice of gynecologic oncology: Chapter 23. 
Corpus: Epithelial tumours. 5th ed. Philadelphia, Pa., London: Lippincott Williams & Wilkins; 2009. 
39. Karlan BY, Bristow RE, Li AJ. Gynecologic oncology: Clinical practice & surgical atlas [Chapter 6: 
Endometrial hyperplasia and carcinoma]. New York: McGraw-Hill Medical; 2012. 
40. Ambros RA, Sherman ME, Zahn CM, Bitterman P, Kurman RJ. Endometrial intraepithelial 
carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. 
Hum Pathol 1995; 26(11):1260–7. 
41. Smith RA, Eschenbach AC von, Wender R, Levin B, Byers T, Rothenberger D et al. American 
Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for 
prostate, colorectal, and endometrial cancers. Also: update 2001--testing for early lung cancer 
detection. CA Cancer J Clin 2001; 51(1):38-75; quiz 77-80. 
42. Endometrial Cancer Screening (PDQ(R)): Health Professional Version. In: PDQ Cancer Information 
Summaries. Bethesda (MD); 2002 . 
43. Purdie DM, Green AC. Epidemiology of endometrial cancer. Best Pract Res Clin Obstet Gynaecol 
2001; 15(3):341–54. 
44. Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. 
Obstet Gynecol 1984; 64(3):417–20. 
45. Azim A, Oktay K. Letrozole for ovulation induction and fertility preservation by embryo 
cryopreservation in young women with endometrial carcinoma. Fertility and Sterility 2007; 
88(3):657–64. 
46. Chen L-m, Berek JS. Endometrial cancer: Epidemiology, risk factors, clinical features, diagnosis, 
and screening: UpToDate; 2011. Available from: URL: 
http://cursoenarm.net/UPTODATE/contents/mobipreview.htm?28/30/29153?source=see_link. 
47. Whitehead MI, Fraser D. Controversies concerning the safety of estrogen replacement therapy. 
American Journal of Obstetrics & Gynecology; 156(5):1313–22. 
48. GRADY D, Gebretsadil T, KERLIKOWSKE K, ERNSTER V, PETITTI D. Hormone replacement therapy 
and endometrial cancer risk: A meta-analysis. Obstetrics & Gynecology 1995; 85(2):304–13. 
49. Pike MC. Age-related factors in cancers of the breast, ovary, and endometrium. Journal of 
chronic disease 1987; (40 (Supplement 2)):59S-69S. 
50. Smith DC, Prentice R, Thompson DJ, Herrmann WL. Association of exogenous estrogen and 
endometrial carcinoma. N Engl J Med 1975; 293(23):1164–7. 
66 | P a g e  
 
51. Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, van Belle G. Progestagen supplementation of 
exogenous oestrogens and risk of endometrial cancer. Lancet 1991; 338(8762):274–7. 
52. Henderson BE, Casagrande JT, Pike MC, Mack T, Rosario I, Duke A. The epidemiology of 
endometrial cancer in young women. British Journal of Cancer 1983; 47(6):749–56. 
53. Hulka BS, Fowler WC, Kaufman DG, Grimson RC, Greenberg BG, Hogue CJ et al. Estrogen and 
endometrial cancer: Cases and two control groups from North Carolina. American Journal of 
Obstetrics and Gynecology 1980; 137(1):92–101. 
54. Weiderpass E, Adami H-O, Baron JA, Magnusson C, Bergstrom R, Lindgren A et al. Risk of 
endometrial cancer following estrogen replacement with and without progestins. Journal of National 
Cancer Institute 1999; 91(13):1131–7.  
55. Persson I, Adami HO, Bergkvist L, Lindgren A, Pettersson B, Hoover R et al. Risk of endometrial 
cancer after treatment with oestrogens alone or in conjunction with progestogens: Results of a 
prospective study. BMJ 1989; 298(6667):147–51. 
56. Henderson BE. The cancer question: an overview of recent epidemiologic and retrospective data. 
American Journal of Obstetrics and Gynecology 1989; 161(6 Pt 2):1859–64. 
57. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer 
in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and 
Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86(7):527–37. 
58. Mignotte H, et al. Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in 
a large French case-control study. Int J Cancer 1998; 76(3):325–30. 
59. Hoskins WJ. Principles and practice of gynecologic oncology. 4th ed. Philadelphia, Pa., London: 
Lippincott Williams & Wilkins; 2005. 
60. Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol 
Oncol 2004; 94(2):256–66. 
61. Bland AE, Calingaert B, Secord AA, Lee PS, Valea FA, Berchuck A et al. Relationship between 
tamoxifen use and high risk endometrial cancer histologic types. Gynecol Oncol 2009; 112(1):150–4. 
62. Siiteri PK. Adipose tissue as a source of hormones. Am J Clin Nutr 1987; 45(1 Suppl):277–82. 
63. Akhmedkhanov A, Zeleniuch-Jacquotte A, Toniolo P. Role of exogenous and endogenous 
hormones in endometrial cancer: review of the evidence and research perspectives. Ann N Y Acad 
Sci 2001; 943:296–315. 
64. Lukanova A, Lundin E, Micheli A, Arslan A, Ferrari P, Rinaldi S et al. Circulating levels of sex 
steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer 2004; 
108(3):425–32. 
65. Nyholm HC, Nielsen AL, Lyndrup J, Dreisler A, Hagen C, Haug E. Plasma oestrogens in 
postmenopausal women with endometrial cancer. Br J Obstet Gynaecol 1993; 100(12):1115–9. 
66. Potischman N, Hoover RN, Brinton LA, Siiteri P, Dorgan JF, Swanson CA et al. Case-control study 
of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst 1996; 88(16):1127–35. 
67. Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C et al. Endometrial cancer: ESMO 
Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2013; 
24(Supplement 6):vi33-vi38. 
67 | P a g e  
 
68. Lu L, Risch H, Irwin ML, Mayne ST, Cartmel B, Schwartz P et al. Long-term overweight and weight 
gain in early adulthood in association with risk of endometrial cancer. Int J Cancer 2011; 
129(5):1237–43. 
69. Brinton LA, Berman ML, Mortel R, Twiggs LB, Barrett RJ, Wilbanks GD et al. Reproductive, 
menstrual, and medical risk factors for endometrial cancer: Results from a case-control study. 
American Journal of Obstetrics and Gynecology 1992; 167(5):1317–25. 
70. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: 
A systematic review and meta-analysis of prospective observational studies. The Lancet 2008; 
371(9612):569–78. 
71. Pellerin GP, Finan MA. Endometrial cancer in women 45 years of age or younger: a 
clinicopathological analysis. American Journal of Obstetrics and Gynecology 2005; 193(5):1640–4. 
72. Thomas HV, Key TJ, Allen DS, Moore JW, Dowsett M, Fentiman IS et al. Re: Reversal of Relation 
Between Body Mass and Endogenous Estrogen Concentrations With Menopausal Status. JNCI 
Journal of the National Cancer Institute 1997; 89(5):396–7. 
73. Amant F, Moerman P, Neven P, Timmerman D, van Limbergen E, Vergote I. Endometrial cancer. 
The Lancet 2005; 366(9484):491–505. 
74. Tao MH, Xu WH, Zheng W, Zhang Z-F, Gao Y-T, Ruan ZX et al. Oral contraceptive and IUD use and 
endometrial cancer: a population-based case-control study in Shanghai, China. Int J Cancer 2006; 
119(9):2142–7. 
75. Fearnley EJ, Marquart L, Spurdle AB, Weinstein P, Webb PM. Polycystic ovary syndrome 
increases the risk of endometrial cancer in women aged less than 50 years: an Australian case-
control study. Cancer Causes Control 2010; 21(12):2303–8. 
76. Chamlian DL, Taylor HB. Endometrial hyperplasia in young women. Obstet Gynecol 1970; 
36(5):659–66. 
77. Lochen ML, Lund E. Childbearing and mortality from cancer of the corpus uteri. Acta Obstet 
Gynecol Scand 1997; 76(4):373–7. 
78. McPherson CP, Sellers TA, Potter JD, Bostick RM, Folsom AR. Reproductive factors and risk of 
endometrial cancer. The Iowa Women's Health Study. Am J Epidemiol 1996; 143(12):1195–202. 
79. Parazzini F, Negri E, La Vecchia C, Benzi G, Chiaffarino F, Polatti A et al. Role of reproductive 
factors on the risk of endometrial cancer. Int J Cancer 1998; 76(6):784–6. 
80. Bevier M, Sundquist J, Hemminki K. Does the time interval between first and last birth influence 
the risk of endometrial and ovarian cancer? Eur J Cancer 2011; 47(4):586–91. 
81. La Vecchia C, Franceschi S, Decarli A, Gallus G, Tognoni G. Risk factors for endometrial cancer at 
different ages. J Natl Cancer Inst 1984; 73(3):667–71. 
82. Xu W-H, Xiang Y-B, Ruan Z-X, Zheng W, Cheng J-R, Dai Q et al. Menstrual and reproductive factors 
and endometrial cancer risk: Results from a population-based case-control study in urban Shanghai. 
Int J Cancer 2004; 108(4):613–9. 
83. Larson J. Estrogens and endometrial carcinoma. Obstet Gynecol 1954; 3(5):551–72. 
84. Levine DA, Lin O, Barakat RR, Robson ME, McDermott D, Cohen L et al. Risk of endometrial 
carcinoma associated with BRCA mutation. Gynecol Oncol 2001; 80(3):395–8. 
68 | P a g e  
 
85. Thompson D, Easton DF. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002; 
94(18):1358–65. 
86. Beiner ME, Finch A, Rosen B, Lubinski J, Moller P, Ghadirian P et al. The risk of endometrial 
cancer in women with BRCA1 and BRCA2 mutations: A prospective study. Gynecol Oncol 2007; 
104(1):7–10. 
87. Chen L-m, Berek JS. Endometrial carcinoma: Epidemiology and risk factors: UpToDate; 2016. 




88. Iqbal J, Ginsburg OM, Wijeratne TD, Howell A, Evans G, Sestak I et al. Endometrial cancer and 
venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast 
cancer: a systematic review. Cancer Treat Rev 2012; 38(4):318–28. 
89. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant 
tamoxifen: Patient-level meta-analysis of randomised trials. The Lancet 2011; 378(9793):771–84. 
90. Wolf DM, Jordan VC. Gynecologic complications associated with long-term adjuvant tamoxifen 
therapy for breast cancer. Gynecol Oncol 1992; 45(2):118–28. 
91. Althuis MD, Sexton M, Langenberg P, Bush TL, Tkaczuk K, Magaziner J et al. Surveillance for 
uterine abnormalities in tamoxifen-treated breast carcinoma survivors. Cancer 2000; 89(4):800–10. 
92. Cohen I, Perel E, Flex D, Tepper R, Altaras MM, Cordoba M et al. Endometrial pathology in 
postmenopausal tamoxifen treatment: comparison between gynaecologically symptomatic and 
asymptomatic breast cancer patients. J Clin Pathol 1999; 52(4):278–82. 
93. Botha MH. Endometrial carcinoma: a South African perspective: review. Southern African Journal 
of Gynaecological Oncology 2009; 1(1):16–20. 
94. Committee Opinion No. 601: Tamoxifen and uterine cancer. Obstet Gynecol 2014; 123(6):1394–
7. 
95. Kessler II. Cancer and diabetes mellitus a review of the literature. Journal of Chronic Diseases 
1971; 23(8):579–600. 
96. Weiderpass E, Persson I, Adami H-O, Magnusson C, Lindgren A, Baron JA. Body size in different 
periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer: 
(Sweden). Cancer Causes and Control 2000; 11(2):185–92. 
97. Parazzini F, La Vecchia C, Negri E, Luca Riboldi G, Surace M, Benzi G et al. Diabetes and 
endometrial cancer: An Italian case-control study. Int. J. Cancer 1999; 81(4):539–42. 
98. Soliman PT, Wu D, Tortolero-Luna G, Schmeler KM, Slomovitz BM, Bray MS et al. Association 
between adiponectin, insulin resistance, and endometrial cancer. Cancer 2006; 106(11):2376–81. 
99. Mulholland HG, Murray LJ, Cardwell CR, Cantwell MM. Dietary glycaemic index, glycaemic load 
and endometrial and ovarian cancer risk: a systematic review and meta-analysis. British Journal of 
Cancer 2008; 99(3):434–41. 
100. Sandles LG. Familial endometrial adenocarcinoma. Clin Obstet Gynecol 1998; 41(1):167–71. 
101. Creasman W, Huh WK. Endometrial carcinoma: Medscape; 2016. Available from: URL: 
http://emedicine.medscape.com/article/254083-overview#a6. 
69 | P a g e  
 
102. PDQ Screening and Prevention Editorial Board. Endometrial cancer prevention: Health 
professional version: National cancer institute; 2016. Available from: URL: 
https://www.cancer.gov/types/uterine/hp/endometrial-prevention-pdq#section/all. 
103. MedLibrary.org. Endometrial cancer: MedLibrary.org. Available from: URL: 
http://medlibrary.org/medwiki/Endometrial_cancer#Protective_factors. 
104. Levi F, La Vecchia C, Decarli A. Cigarette smoking and the risk of endometrial cancer. European 
Journal of Cancer and Clinical Oncology 1987; 23(7):1025–9. 
105. MacMahon B, Trichopoulos D, Cole P, Brown J. Cigarette smoking and urinary estrogens. New 
England Journal of Medicine 1982; 307(17):1062–5. 
106. Baron JA. Smoking and estrogen-related disease. Am J Epidemiol 1984; 119(1):9–22. 
107. Franks AL, Kendrick JS, Tyler CW. Postmenopausal smoking, estrogen replacement therapy, and 
the risk of endometrial cancer. American Journal of Obstetrics and Gynecology 1987; 156(1):20–3. 
108. Schouten LJ, Goldbohm RA, van den Brandt PA. Anthropometry, physical activity, and 
endometrial cancer risk: results from the Netherlands Cohort Study. J Natl Cancer Inst 2004; 
96(21):1635–8. 
109. Furberg A-S, Thune I. Metabolic abnormalities (hypertension, hyperglycemia and overweight), 
lifestyle (high energy intake and physical inactivity) and endometrial cancer risk in a Norwegian 
cohort. Int J Cancer 2003; 104(6):669–76. 
110. Moradi T, Weiderpass E, Signorello LB, Persson I, Nyrén O, Adami H-O. Physical activity and 
postmenopausal endometrial cancer risk (Sweden). Cancer Causes and Control 2000; 11(9):829–37. 
111. Friedenreich C, Cust A, Lahmann PH, Steindorf K, Boutron-Ruault M-C, Clavel-Chapelon F et al. 
Physical activity and risk of endometrial cancer: the European prospective investigation into cancer 
and nutrition. Int J Cancer 2007; 121(2):347–55. 
112. Friedenreich CM, Orenstein MR. Physical activity and cancer prevention: etiologic evidence and 
biological mechanisms. J Nutr 2002; 132(11 Suppl):3456S-3464S. 
113. Renaud M-C, Le T. Epidemiology and Investigations for Suspected Endometrial Cancer: Joint 
SOGC-GOC-SCC Clinical Practice Guideline. Journal of obstetrics and gynaecology Canada 2013; 35(4 
eSupplement C):S1-S9. 
114. Investigation of post-menopausal bleeding: A national clinical guideline; 2002. (SIGN; vol 61). 
Available from: URL: http://www.sign.ac.uk/guidelines/fulltext/61/. 
115. Dijkhuizen FP, Mol BW, Brolmann HA, Heintz AP. The accuracy of endometrial sampling in the 
diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer 2000; 
89(8):1765–72. 
116. Mao Y, Wan X, Chen Y, Lv W, Xie X. Evaluation of the accuracy of intra-operative gross 
examination for the surgical management of endometrial cancer. Eur J Obstet Gynecol Reprod Biol 
2008; 141(2):179–82. 
117. Bakkum-Gamez JN, Gonzalez-Bosquet J, Laack NN, Mariani A, Dowdy SC. Current issues in the 
management of endometrial cancer. Mayo Clin Proc 2008; 83(1):97–112. 
118. Goldstein SR, Nachtigall M, Snyder JR, Nachtigall L. Endometrial assessment by vaginal 
ultrasonography before endometrial sampling in patients with postmenopausal bleeding. American 
Journal of Obstetrics and Gynecology 1990; 163(1 Pt 1):119–23. 
70 | P a g e  
 
119. Leitao MM, JR, Kehoe S, Barakat RR, Alektiar K, Gattoc LP, Rabbitt C et al. Comparison of D&C 
and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma. 
Gynecol Oncol 2009; 113(1):105–8. 
120. Munstedt K, Grant P, Woenckhaus J, Roth G, Tinneberg H-R. Cancer of the endometrium: 
current aspects of diagnostics and treatment. World J Surg Oncol 2004; 2:24. 
121. Chan JK, Kapp DS. Role of complete lymphadenectomy in endometrioid uterine cancer. The 
Lancet Oncology 2007; 8(9):831–41. 
122. Brand A, Dubuc-Lissoir J, Ehlen TG, Plante M. Diagnosis of endometrial cancer in women with 
abnormal vaginal bleeding.: Policy statement No. 86. Journal of obstetrics and gynaecology Canada 
2000; 22(1):102–4. 
123. Kotdawala P, Kotdawala S, Nagar N. Evaluation of endometrium in peri-menopausal abnormal 
uterine bleeding. J Midlife Health 2013; 4(1):16–21. 
124. Buchanan EM, Weinstein LC, Hillson C. Endometrial cancer. Am Fam Physician 2009; 
80(10):1075–80. 
125. Ribeiro CT, Rosa-E-Silva JC, Silva-de-Sa MF, Rosa-E-Silva ACJdS, Poli Neto OB, Candido Dos Reis 
FJ et al. Hysteroscopy as a standard procedure for assessing endometrial lesions among 
postmenopausal women. Sao Paulo Med J 2007; 125(6):338–42. 
126. Saha TK, Amer SA, Biss J, Thakare H, Williams S, Farrell T et al. The validity of transvaginal 
ultrasound measurement of endometrial thickness: A comparison of ultrasound measurement with 
direct anatomical measurement. BJOG: An International Journal of Obstetrics & Gynaecology 2004; 
111(12):1419–24. 
127. Saso S, Chatterjee J, Georgiou E, Ditri AM, Smith JR, Ghaem-Maghami S. Endometrial cancer. 
BMJ 2011; 343:d3954. 
128. ACOG Committee Opinion No. 426: The role of transvaginal ultrasonography in the evaluation 
of postmenopausal bleeding. Obstet Gynecol 2009; 113(2 Pt 1):462–4. 
129. Sathiyathasan S, Jeyanthan K, Khoo CL. Asymptomatic postmenopausal women with 
sonographically thickened endometrium. What do we do? OJOG 2013; 03(08):631–3. 
130. American College of Obstetricians and Gynecologists. The role of transvaginal ultrasonography 
in the evaluation of postmenopausal bleeding: ACOG Committee Opinion No. 440 [Reaffirmed 
2015]; 2009. Available from: URL: https://www.acog.org/Resources-And-Publications/Committee-
Opinions/Committee-on-Gynecologic-Practice/The-Role-of-Transvaginal-Ultrasonography-in-the-
Evaluation-of-Postmenopausal-Bleeding. 
131. Varner RE, Sparks JM, Cameron CD, Roberts LL, Soong SJ. Transvaginal sonography of the 
endometrium in postmenopausal women. Obstet Gynecol 1991; 78(2):195–9. 
132. Granberg S, Wikland M, Karlsson B, Norstrom A, Friberg LG. Endometrial thickness as measured 
by endovaginal ultrasonography for identifying endometrial abnormality. American Journal of 
Obstetrics and Gynecology 1991; 164(1 Pt 1):47–52. 
133. Conoscenti G, Meir YJ, Fischer-Tamaro L, Maieron A, Natale R, D'Ottavio G et al. Endometrial 
assessment by transvaginal sonography and histological findings after D & C in women with 
postmenopausal bleeding. Ultrasound Obstet Gynecol 1995; 6(2):108–15. 
71 | P a g e  
 
134. Dorum A, Kristensen GB, Langebrekke A, Sornes T, Skaar O. Evaluation of endometrial thickness 
measured by endovaginal ultrasound in women with postmenopausal bleeding. Acta Obstet Gynecol 
Scand 1993; 72(2):116–9. 
135. Vuento MH, Pirhonen JP, Mäkinen JI, Tyrkkö JE, Laippala PJ, Grönroos M et al. Screening for 
endometrial cancer in asymptomatic postmenopausal women with conventional and colour Doppler 
sonography. BJOG: An International Journal of Obstetrics & Gynaecology 1999; 106(1):14–20. 
Available from: URL: http://dx.doi.org/10.1111/j.1471-0528.1999.tb08079.x. 
136. Smith-Bindman R, Weiss E, Feldstein V. How thick is too thick? When endometrial thickness 
should prompt biopsy in postmenopausal women without vaginal bleeding. Ultrasound Obstet 
Gynecol 2004; 24(5):558–65. 
137. Hulka CA, Hall DA, McCarthy K, Simeone JF. Endometrial polyps, hyperplasia, and carcinoma in 
postmenopausal women: differentiation with endovaginal sonography. Radiology 1994; 191(3):755–
8. 
138. Fong K, Kung R, Lytwyn A, Trudeau M, Chapman W, Nugent P et al. Endometrial evaluation with 
transvaginal US and hysterosonography in asymptomatic postmenopausal women with breast 
cancer receiving tamoxifen. Radiology 2001; 220(3):765–73. 
139. Hann LE, Giess CS, Bach AM, Tao Y, Baum HJ, Barakat RR. Endometrial thickness in tamoxifen-
treated patients: correlation with clinical and pathologic findings. American journal of roentgenology 
1997; 168(3):657–61. 




141. Feldman S. Evaluation of the endometrium for malignant or premalignant disease: UpToDate; 




142. Sit ASY, Modugno F, Hill LM, Martin J, Weissfeld JL. Transvaginal ultrasound measurement of 
endometrial thickness as a biomarker for estrogen exposure. Cancer Epidemiol Biomarkers Prev 
2004; 13(9):1459–65. 
143. Plaxe SC. Endometrial carcinoma: Pretreatment evaluation, staging, and surgical treatment: 
UpToDate; 2014. Available from: URL: https://www.uptodate.com/contents/endometrial-
carcinoma-pretreatment-evaluation-staging-and-surgical-treatment?source=related_link. 
144. Benedet. Editorial. Int J Gynaecol Obstet 2000; 70(2):207–8. 
145. Mavromatis ID, Antonopoulos CN, Matsoukis IL, Frangos CC, Skalkidou A, Creatsas G et al. 
Validity of intraoperative gross examination of myometrial invasion in patients with endometrial 
cancer: a meta-analysis. Acta Obstet Gynecol Scand 2012; 91(7):779–93. 
146. Fanning J, Tsukada Y, Piver MS. Intraoperative frozen section diagnosis of depth of myometrial 
invasion in endometrial adenocarcinoma. Gynecol Oncol 1990; 37(1):47–50. 
147. Goff BA, Rice LW. Assessment of depth of myometrial invasion in endometrial adenocarcinoma. 
Gynecol Oncol 1990; 38(1):46–8. 
72 | P a g e  
 
148. Quinlivan JA, Petersen RW, Nicklin JL. Accuracy of frozen section for the operative management 
of endometrial cancer. BJOG 2001; 108(8):798–803. 
149. Egle D, Grissemann B, Zeimet AG, Müller-Holzner E, Marth C. Validation of intraoperative risk 
assessment on frozen section for surgical management of endometrial carcinoma. Gynecol Oncol 
2008; 110(3):286–92. 
150. Walker JL, Piedmonte MR, Spirtos NM, Eisenkop SM, Schlaerth JB, Mannel RS et al. Laparoscopy 
compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic 
Oncology Group Study LAP2. J Clin Oncol 2009; 27(32):5331–6. 
151. Mourits MJE, Bijen CB, Arts HJ, ter Brugge HG, van der Sijde R, Paulsen L et al. Safety of 
laparoscopy versus laparotomy in early-stage endometrial cancer: A randomised trial. The Lancet 
Oncology 2010; 11(8):763–71. 
152. Janda M, Gebski V, Brand A, Hogg R, Jobling TW, Land R et al. Quality of life after total 
laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer 
(LACE): A randomised trial. The Lancet Oncology 2010; 11(8):772–80. 
153. Kornblith AB, Huang HQ, Walker JL, Spirtos NM, Rotmensch J, Cella D. Quality of life of patients 
with endometrial cancer undergoing laparoscopic international federation of gynecology and 
obstetrics staging compared with laparotomy: a Gynecologic Oncology Group study. J Clin Oncol 
2009; 27(32):5337–42. 
154. Palomba S, Falbo A, Mocciaro R, Russo T, Zullo F. Laparoscopic treatment for endometrial 
cancer: a meta-analysis of randomized controlled trials (RCTs). Gynecol Oncol 2009; 112(2):415–21. 
155. Kitchener H, Swart AMC, Qian Q, Amos C, Parmar MKB. Efficacy of systematic pelvic 
lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009; 
373(9658):125–36. 
156. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic 
spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987; 60(8 
Suppl):2035–41. 
157. Boronow RC, Morrow CP, Creasman WT, Disaia PJ, Silverberg SG, Miller A et al. Surgical staging 
in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet Gynecol 1984; 
63(6):825–32. 
158. Takeshima N, Hirai Y, Tanaka N, Yamawaki T, Yamauchi K, Hasumi K. Pelvic lymph node 
metastasis in endometrial cancer with no myometrial invasion. Obstet Gynecol 1996; 88(2):280–2. 
159. Pierga JY, Dieras V, Paraiso D, Dorval T, Palangie T, Beuzeboc P et al. Treatment of advanced or 
recurrent endometrial carcinoma with combination of etoposide, cisplatin, and 5-fluorouracil: a 
phase II study. Gynecol Oncol 1996; 60(1):59–63. 
160. Chan JK, Wu H, Cheung MK, Shin JY, Osann K, Kapp DS. The outcomes of 27,063 women with 
unstaged endometrioid uterine cancer. Gynecol Oncol 2007; 106(2):282–8. 
161. Mariani A, Webb MJ, Keeney GL, Haddock MG, Calori G, Podratz KC. Low-risk corpus cancer: is 
lymphadenectomy or radiotherapy necessary? American Journal of Obstetrics and Gynecology 2000; 
182(6):1506–19. 
162. Grigsby PW, Perez CA, Kuten A, Simpson JR, Garcia DM, Camel HM et al. Clinical stage I 
endometrial cancer: prognostic factors for local control and distant metastasis and implications of 
the new FIGO surgical staging system. Int J Radiat Oncol Biol Phys 1992; 22(5):905–11. 
73 | P a g e  
 
163. Kilgore LC, Partridge EE, Alvarez RD, Austin JM, Shingleton HM, Noojin F3 et al. Adenocarcinoma 
of the endometrium: survival comparisons of patients with and without pelvic node sampling. 
Gynecol Oncol 1995; 56(1):29–33. 
164. Abu-Rustum NR, Gomez JD, Alektiar KM, Soslow RA, Hensley ML, Leitao MM, JR et al. The 
incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients 
with negative pelvic lymph nodes. Gynecol Oncol 2009; 115(2):236–8. 
165. Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N. Survival effect of para-aortic 
lymphadenectomy in endometrial cancer (SEPAL study): A retrospective cohort analysis. The Lancet 
2010; 375(9721):1165–72. 
166. Frumovitz M, Levenback CF. Is lymphatic mapping in uterine cancer feasible? Ann Surg Oncol 
2008; 15(7):1815–7. 
167. Kang S, Yoo HJ, Hwang JH, Lim M-C, Seo S-S, Park S-Y. Sentinel lymph node biopsy in 
endometrial cancer: meta-analysis of 26 studies. Gynecol Oncol 2011; 123(3):522–7. 
168. Robison K, Holman LL, Moore RG. Update on sentinel lymph node evaluation in gynecologic 
malignancies. Curr Opin Obstet Gynecol 2011; 23(1):8–12. 
169. Niikura H, Okamura C, Utsunomiya H, Yoshinaga K, Akahira J, Ito K et al. Sentinel lymph node 
detection in patients with endometrial cancer. Gynecol Oncol 2004; 92(2):669–74. 
170. Sonoda Y, Zerbe M, Smith A, Lin O, Barakat RR, Hoskins WJ. High incidence of positive 
peritoneal cytology in low-risk endometrial cancer treated by laparoscopically assisted vaginal 
hysterectomy. Gynecol Oncol 2001; 80(3):378–82. 
171. Mais V, Peiretti M, Gargiulo T, Parodo G, Cirronis MG, Melis GB. Intraoperative sentinel lymph 
node detection by vital dye through laparoscopy or laparotomy in early endometrial cancer. J Surg 
Oncol 2010; 101(5):408–12. 
172. Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD et al. A phase III trial of 
surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial 
adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92(3):744–51. 
173. Plaxe SC, Mundt AJ. Approach to adjuvant treatment of endometrial cancer: UpToDate; 2016. 




174. Huh WK, Straughn JM, JR, Mariani A, Podratz KC, Havrilesky LJ, Alvarez-Secord A et al. Salvage 
of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a 
multiinstitutional experience. Int J Gynecol Cancer 2007; 17(4):886–9. 
175. Awtrey CS, Cadungog MG, Leitao MM, Alektiar KM, Aghajanian C, Hummer AJ et al. Surgical 
resection of recurrent endometrial carcinoma. Gynecol Oncol 2006; 102(3):480–8. 
176. Barakat RR, Goldman NA, Patel DA, Venkatraman ES, Curtin JP. Pelvic exenteration for recurrent 
endometrial cancer. Gynecol Oncol 1999; 75(1):99–102. 
177. Barlin JN, Puri I, Bristow RE. Cytoreductive surgery for advanced or recurrent endometrial 
cancer: a meta-analysis. Gynecol Oncol 2010; 118(1):14–8. 
178. Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a 
systematic review. Int J Gynecol Cancer 2007; 17(5):964–78. 
74 | P a g e  
 
179. Kong A, Johnson N, Kitchener HC, Lawrie TA. Adjuvant radiotherapy for stage I endometrial 
cancer. Cochrane Database Syst Rev 2012; (4):CD003916. 
180. Lentz GM. Comprehensive gynecology. 6th ed. Philadelphia: Mosby Elsevier; 2013, ©2012. 
181. Sylvestre VT, Dunton CJ. Treatment of recurrent endometrial stromal sarcoma with letrozole: a 
case report and literature review. Horm Cancer 2010; 1(2):112–5. 
182. Elit L, Hirte H. Current status and future innovations of hormonal agents, chemotherapy and 
investigational agents in endometrial cancer. Curr Opin Obstet Gynecol 2002; 14(1):67–73. 
183. Singh M, Zaino RJ, Filiaci VJ, Leslie KK. Relationship of estrogen and progesterone receptors to 
clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study. 
Gynecol Oncol 2007; 106(2):325–33. 
184. Carlson JA, JR, Allegra JC, Day TG, JR, Wittliff JL. Tamoxifen and endometrial carcinoma: 
alterations in estrogen and progesterone receptors in untreated patients and combination hormonal 
therapy in advanced neoplasia. American Journal of Obstetrics and Gynecology 1984; 149(2):149–53. 
185. Jeyarajah AR, Gallagher CJ, Blake PR, Oram DH, Dowsett M, Fisher C et al. Long-term follow-up 
of gonadotrophin-releasing hormone analog treatment for recurrent endometrial cancer. Gynecol 
Oncol 1996; 63(1):47–52. 
186. Asbury RF, Brunetto VL, Lee RB, Reid G, Rocereto TF. Goserelin acetate as treatment for 
recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Am J Clin Oncol 2002; 
25(6):557–60. 
187. Gunthert AR, Ackermann S, Beckmann MW, Camara O, Kiesel L, Rensing K et al. Phase II study 
of weekly docetaxel in patients with recurrent or metastatic endometrial cancer: AGO Uterus-4. 
Gynecol Oncol 2007; 104(1):86–90. 
188. Carey MS, Gawlik C, Fung-Kee-Fung M, Chambers A, Oliver T. Systematic review of systemic 
therapy for advanced or recurrent endometrial cancer. Gynecol Oncol 2006; 101(1):158–67. 
189. Pignata S, Scambia G, Pisano C, Breda E, Di Maio M, Greggi S et al. A multicentre phase II study 
of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with 
advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian 
Trials in Ovarian Cancer and Gynecologic Malignancies) group. British Journal of Cancer 2007; 
96(11):1639–43. 
190. Nicolaije KAH, Ezendam NPM, Vos MC, Boll D, Pijnenborg JMA, Kruitwagen RFPM et al. Follow-
up practice in endometrial cancer and the association with patient and hospital characteristics: a 
study from the population-based PROFILES registry. Gynecol Oncol 2013; 129(2):324–31. 
191. Kurra V, Krajewski KM, Jagannathan J, Giardino A, Berlin S, Ramaiya N. Typical and atypical 
metastatic sites of recurrent endometrial carcinoma. Cancer Imaging 2013; 13:113–22. 
192. Vale CL, Tierney J, Bull SJ, Symonds PR. Chemotherapy for advanced, recurrent or metastatic 
endometrial carcinoma. Cochrane Database Syst Rev 2012; (8):CD003915. 
193. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 
65, August 2005: management of endometrial cancer. Obstet Gynecol 2005; 106(2):413–25. 
194. Huang GS, Chiu LG, Gebb JS, Gunter MJ, Sukumvanich P, Goldberg GL et al. Serum CA125 
predicts extrauterine disease and survival in uterine carcinosarcoma. Gynecol Oncol 2007; 
107(3):513–7. 
75 | P a g e  
 
195. Hsieh C-H, ChangChien C-C, Lin H, Huang E-Y, Huang C-C, Lan K-C et al. Can a preoperative CA 
125 level be a criterion for full pelvic lymphadenectomy in surgical staging of endometrial cancer? 
Gynecol Oncol 2002; 86(1):28–33. 
196. Dotters DJ. Preoperative CA 125 in endometrial cancer: is it useful? American Journal of 
Obstetrics and Gynecology 2000; 182(6):1328–34. 
197. Todo Y, Sakuragi N, Nishida R, Yamada T, Ebina Y, Yamamoto R et al. Combined use of magnetic 
resonance imaging, CA 125 assay, histologic type, and histologic grade in the prediction of lymph 
node metastasis in endometrial carcinoma. American Journal of Obstetrics and Gynecology 2003; 
188(5):1265–72. 
198. Powell JL, Hill KA, Shiro BC, Diehl SJ, Gajewski WH. Preoperative serum CA-125 levels in treating 
endometrial cancer. J Reprod Med 2005; 50(8):585–90. 
199. Chung HH, Kim JW, Park N-H, Song Y-S, Kang S-B, Lee H-P. Use of preoperative serum CA-125 
levels for prediction of lymph node metastasis and prognosis in endometrial cancer. Acta Obstet 
Gynecol Scand 2006; 85(12):1501–5. 
200. Kim HS, Park C-Y, Lee J-M, Lee J-K, Cho C-H, Kim S-M et al. Evaluation of serum CA-125 levels for 
preoperative counseling in endometrioid endometrial cancer: a multi-center study. Gynecol Oncol 
2010; 118(3):283–8. 
201. Kinkel K, Kaji Y, Yu KK, Segal MR, Lu Y, Powell CB et al. Radiologic staging in patients with 
endometrial cancer: a meta-analysis. Radiology 1999; 212(3):711–8. 
202. Beddy P, Moyle P, Kataoka M, Yamamoto AK, Joubert I, Lomas D et al. Evaluation of depth of 
myometrial invasion and overall staging in endometrial cancer: comparison of diffusion-weighted 
and dynamic contrast-enhanced MR imaging. Radiology 2012; 262(2):530–7. 
203. Selman TJ, Mann CH, Zamora J, Khan KS. A systematic review of tests for lymph node status in 
primary endometrial cancer. BMC Womens Health 2008; 8:8. 
204. Zaino R, Whitney C, Brady MF, DeGeest K, Burger RA, Buller RE. Simultaneously detected 
endometrial and ovarian carcinomas--a prospective clinicopathologic study of 74 cases: a 
gynecologic oncology group study. Gynecol Oncol 2001; 83(2):355–62. 
205. Soliman PT, Slomovitz BM, Broaddus RR, Sun CC, Oh JC, Eifel PJ et al. Synchronous primary 
cancers of the endometrium and ovary: a single institution review of 84 cases. Gynecol Oncol 2004; 
94(2):456–62. 
206. Walsh C, Holschneider C, Hoang Y, Tieu K, Karlan B, Cass I. Coexisting ovarian malignancy in 
young women with endometrial cancer. Obstet Gynecol 2005; 106(4):693–9. 
207. Wegner RE, Beriwal S, Heron DE, Richard SD, Kelly JL, Edwards RP et al. Definitive radiation 
therapy for endometrial cancer in medically inoperable elderly patients. Brachytherapy 2010; 
9(3):260–5. 
208. Plaxe SC, Mundt AJ. Treatment of low-risk endometrial cancer: UpToDate; 2015. Available from: 
URL: https://www.uptodate.com/contents/treatment-of-low-risk-endometrial-
cancer?source=see_link. 




76 | P a g e  
 
210. Salani R, Backes FJ, Fung MFK, Holschneider CH, Parker LP, Bristow RE et al. Posttreatment 
surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of 
Gynecologic Oncologists recommendations. American Journal of Obstetrics and Gynecology 2011; 
204(6):466–78. 
211. Novetsky AP, Kuroki LM, Massad LS, Hagemann AR, Thaker PH, Powell MA et al. The Utility and 
Management of Vaginal Cytology After Treatment for Endometrial Cancer. Obstetrics & Gynecology 
2013; 121(1):129–35. 
212. Ang C, Bryant A, Barton DPJ, Pomel C, Naik R. Exenterative surgery for recurrent gynaecological 
malignancies. Cochrane Database Syst Rev 2014; (2):CD010449. 
213. Lee NK, Cheung MK, Shin JY, Husain A, Teng NN, Berek JS et al. Prognostic factors for uterine 
cancer in reproductive-aged women. Obstet Gynecol 2007; 109(3):655–62. 
214. International Agency for Research of Cancer (WHO). Cancer Incidence in Five Continents Vol. 
VIII: IARC Scientific Publication No. 155; 2002. 
215. Ali AT. Risk factors for endometrial cancer among black South African women: A case control 
study. Johannesburg, South Africa: University of Witwatersrand; 2010. 
216. Zhang Y, Liu H, Yang S, Zhang J, Qian L, Chen X. Overweight, obesity and endometrial cancer 
risk: results from a systematic review and meta-analysis. Int J Biol Markers 2014; 29(1):e21-9. 
217. Stein L, Urban MI, O'Connell D, Yu XQ, Beral V, Newton R et al. The spectrum of human 
immunodeficiency virus-associated cancers in a South African black population: results from a case-
control study, 1995-2004. Int J Cancer 2008; 122(10):2260–5. 
218. Franceschi S, Dal Maso L, La Vecchia C. Advances in the epidemiology of HIV-associated non-
Hodgkin's lymphoma and other lymphoid neoplasms. Int. J. Cancer 1999; 83(4):481–5. 
219. Newton R, Ngilimana P-J, Grulich A, Beral V, Sindikubwabo B, Nganyira A et al. Cancer in 
Rwanda. Int. J. Cancer 1996; 66(1):75–81. 
220. Cuzick J. Chemoprevention of breast cancer. Breast Cancer 2008; 15(1):10–6. 
221. Jones E, Frain BM, Crabtree W. Clinical significance of reporting benign-appearing endometrial 
cells in Pap tests in women aged 40 years and over. Acta Cytol 2009; 53(1):18–23. 
222. Zucchetto A, Serraino D, Polesel J, Negri E, Paoli A de, Dal Maso L et al. Hormone-related factors 
and gynecological conditions in relation to endometrial cancer risk. European Journal of Cancer 
Prevention 2009; 18(4):316–21. Available from: URL: 
http://journals.lww.com/eurjcancerprev/Fulltext/2009/08000/Hormone_related_factors_and_gyne
cological.8.aspx. 
223. Schonfeld SJ, Hartge P, Pfeiffer RM, Freedman DM, Greenlee RT, Linet MS et al. An aggregated 
analysis of hormonal factors and endometrial cancer risk by parity. Cancer 2013; 119(7):1393–401. 
224. Urban M, Banks E, Egger S, Canfell K, O'Connell D, Beral V et al. Injectable and oral 
contraceptive use and cancers of the breast, cervix, ovary, and endometrium in black South African 
women: case-control study. PLoS Med 2012; 9(3):e1001182. 
225. Lucenteforte E, Bosetti C, Talamini R, Montella M, Zucchetto A, Pelucchi C et al. Diabetes and 
endometrial cancer: effect modification by body weight, physical activity and hypertension. British 
Journal of Cancer 2007; 97(7):995–8. 
77 | P a g e  
 
226. Barone BB, Yeh H-C, Snyder CF, Peairs KS, Stein KB, Derr RL et al. Long-term all-cause mortality 
in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 
2008; 300(23):2754–64. 
227. Soler M, Chatenoud L, Negri E, Parazzini F, Franceschi S, La Vecchia C. Hypertension and 
Hormone-Related Neoplasms in Women. Hypertension 1999; 34(2):320–5. 
228. Robertson G. Screening for endometrial cancer. Med J Aust 2003; 178(12):657–9. 
229. Bree RL, Carlos RC. US for postmenopausal bleeding. Radiology. 2002; 222(3):595–8. 
230. Statistics South Africa. Statistical release (revised): Census 2011; 2012. Available from: URL: 
http://www.statssa.gov.za/publications/P03014/P030142011.pdf. 
231. Santoso JT, Barton G, Riedley-Malone S, Wan JY. Obesity and perioperative outcomes in 
endometrial cancer surgery. Arch Gynecol Obstet 2012; 285(4):1139–44. 
232. Yoney A. Treatment outcome and prognostic factors in intermediate risk stage I endometrial 
carcinoma. Indian J Cancer 2014; 51(3):309–14. 
233. Foote AJ, Proietto A. Stage 1 endometrial cancer: treatment modalities and factors influencing 
recurrence. Aust N Z J Obstet Gynaecol 1994; 34(4):448–52. 





















78 | P a g e  
 
Annexure 1: Data sheet 
CLINICAL PROFILE AND MANAGEMENTOF WOMEN TREATED WITH ENDOMETRIAL 
ADENO CARINOMA IN DURBAN, SOUTH AFRICA 
 
                           STUDY No:   
  PARITY:                                RACE:  
 
AGE AT FIRST Dx:        DATE OF FIRST Dx:   
 
 
AGE AT RECURRANCE:                                TIME TO RECURRANCE: 
 
SITE OF RECURRANCE:   
 
 
MENARCHE:   MENOPAUSE:               AGE OF MENOPAUSE:   
 
   
HPT:    DM:   HX Ca Breast:   PCOS:  
 
COC USE:   DURATION OF COC USE:  TAMOXIFEN USE:   
 
 
HIV:   CD4 COUNT:   PRESENTATION:   
 
 
BMI:    HEIGHT:   WEIGHT:   
 
 
PAP SMEAR RESULTS:   
 
 
PIPELLE:   PIPELLE RESULTS:   
 
 
HRT USE:    TYPE OF HRT USE:    
 
 
HB:    TV ULTRASOUND:    ET : 
 
Mx:    SURGICAL Mx:  
 DURATION OF Sx:   
 
 
DAYS IN HOSP:   POST OP COMP.:  
 
   
USE OF LMWH:  PHYSIO:  
 
HISTOLOGY RESULTS:     FIGO STAGING:   
 
 
RADIO Tx:                               TYPE OF RADIO                                                    Tx:  CH 
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